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GENERAL INTRODUCTION 
This research has focussed on two biomolecules, viz., mitogen regulated 
protein/ proliferin (mrp/plf) and basic fibroblast growth factor (bFGF). Experiments 
have been perfonmed directed at understanding how bFGF regulates mrp/plf gene 
expression in 3T3 ceils. 
Mitogen Regulated Protein/ Proliferin (MRP/PLF) 
Mitogen regulated protein (MRP) was first identified and named by Nilsen-
Hamilton et al. (1980) as a protein that is secreted into the growth medium by ceils in 
culture in response to mitogens. Linzer and Nathans (1983, 1984) described two 
cDNA sequences derived from mRNA species that were expressed in proliferating 
cells. The protein encoded by these cDNA molecules was called proliferin (PLF). The 
derived amino acid sequence of the PLFs was almost completely identical to that of 
MRP (Connor et al., 1989) and these two proteins are also antigenically identical 
(Nilsen-Hamilton et al., 1987) thus proving that MRP and PLF are the same protein. 
Therefore, throughout this thesis, in general, this protein and its gene will be referred 
to as MRP/PLF and mrp/plf respectively and in particular instances, wherever 
necessary, by their specific names. 
MRP/PLF is a secreted glycoprotein of 34 kDa relative molecular mass. Its 
amino acid sequence has 32% identity to mouse prolactin, 37% identity to bovine 
prolactin and 22% identity to bovine growth hormone and therefore it has been 
classified as a member of the prolactin/growth hormone gene superfamily (Linzer and 
Nathans, 1985). It is synthesized by the trophoblastic giant cells of murine placentae 
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and secreted into the maternal blood stream during days 9 and 13 of gestation with 
peak levels occuring at day 11 (Linzer et al., 1985; Lee et., 1988; Nilsen-Hamilton et 
al., 1988; 1991). The period of expression corresponds to the active growth state of 
the embryo and the placenta {ibid) suggesting physiological functions for this protein 
in mouse development. 
MRP/PLF is recognized by two forms of receptors. Molecules of MRP/PLF 
destined to the lysosomes have mannose-6-phosphate moities and are recognized by 
the cation-independent mannose-6-phosphate receptor (Lee and Nathans, 1988). A 
second receptor for MRP/PLF has been identified in mouse mammary glands and uteri 
(Nelson et al., 1995). Peak levels of this second receptor, which is the MRP/PLF-
specific receptor speculated to be involved in MRP/PLF signal transduction, occurs at 
day 11 of gestation. Purified MRP/PLF stimulates DNA synthesis in primary cultures 
of uteri obtained from mice at day 11 of gestation (Nelson et al., 1995). It is therefore 
predicted to be a uterine growth factor that promotes growth of the uterus during 
gestation. This does not exclude the possibility that it may also be involved in the 
development of the embryo. Overexpression of MRP/PLF inhibits myogenic 
differentiation of C3H/10T1/2 cells (Wilder and Linzer, 1989). This mechanism 
involves the inactivation of a CArG-binding factor necessary for transcription driven by 
myogenic-specific promoters (Muscat et al., 1991). Another function for MRP/PLF is 
its possible role in immortalization of 3T3 cells (Malyankar et al., 1994). 
Cell lines such as Swiss 3T3 (Nilsen-Hamilton et al., 1980), Balb/c 3T3 (Linzer 
and Nathans, 1983), BNL, Kreb's ascites carcinoma (Linzer and Nathans, 1984), TNR-
9 (Fienup et al., 1988), and C3H 10T1/2 (Wilder and Linzer, 1989) express MRP/PLF 
in culture. In some of these cell lines MRP/PLF expression is regulated by mitogens. 
Balb/c3T3 cells express MRP/PLF in response to serum (Linzer and Nathans, 1984; 
Parfett et al., 1985) and platelet derived growth factor (PDGF; Linzer and Nathans, 
1984). In Swiss 3T3 cells epidermal growth factor (EGF), transfonning growth factor-a 
(TGF-cc) and basic fibroblast growth factor (bFGF) (Nilsen-Hamilton et al., 1980,1988 
and 1991), phorbol myristate acetate (PMA; also referred to as TPA; Fienup et al., 
1986) and serum (Nilsen-Hamilton et al., 1980, Parfett et al., 1985) stimulate the 
expression of MRP/PLF. Of these mitogens bFGF appears to have the greatest 
stimulatory effect in 3T3 cells (Nilsen-Hamilton, unpublished observation). 
MRP/PLF is encoded by multiple genes. It has been reported that there are four 
(Wilder and Linzer, 1988), five (Connor et al., 1989), or six (Linzer and Mordaq, 1987) 
copies of the gene in the mouse genome. Of these gene copies, the full length 
genomic sequence for only one has been cloned (Connor et al., 1989). This gene is 
designated mrp/plf3. This clone obtained from a Swiss mouse embryo fibroblast 
genomic library includes all of its introns and exons and 2000 bp of its 5' upstream 
sequence as well {ibid). Partial genomic sequences that include the first exon, 300 
bp of the first intron and 1100 bp of the 5'upstream sequences for two other genes 
have also been cloned (Linzer and Mordacq, 1987). These two clones, designated 
plf42 and plf149, and were obtained from a Balb/c mouse genomic library. The 
mrp/plf3 promoter has been sequenced upto -1100 bp (Connor et al., 1989) while plf42 
and plf149 promoters have been sequenced upto -578 bp (Linzer and Mordacq, 1987). 
Comparison of the sequence -578 to +99 (end of the first exon) between the three 
genes indicates that mrp/plf3 is 98.4% identical to plf42 and 97.4% identical to plf149 
(Connor et al., 1989) while plf42 and plf149 are 97.5% identical. Several transcription 
factor binding DNA consensus motifs occur within the mrp/plf3 5' upstream sequence 
(Figure 1). Two of these elements, the composite glucocorticoid response element and 
the TPA-inducible element, were identified in this promoter (Mordacq and Linzer, 
1989). 
Two complete mip/plf cDUA sequences one called plf1, from a Balb/c 3T3 cell 
cDNA library (Linzer and Nathans, 1984) and the second called plf2, from a Balb/c 
mouse placenta cDNA library (Linzer et al., 1985) have also been cloned. A partial 
sequence of a third MRP/PLF cDNA, called mrp/plf3 was cloned from BNL cells 
(Parfett et al., 1985). The sequence information reveals that MRP/PLF mRNA has one 
open reading frame that encodes a protein of 224 amino acids with the first 29 amino 
acids resembling the signal sequences of prehormones, including prolactins (Linzer 
and Nathans, 1984). Therefore, the mature protein is expected to be made of 195 
amino acids. The consensus N-glycosylation signal Asn-X-Ser appears at three 
locations within this protein {ibid). The amino acid sequence deduced from the PLF1 
and PLF2 cDNAs and the coding sequence of mrp/plf3 are almost identical (Figure 2); 
out of the 195 amino acids in the mature protein, PLF1 and PLF2 differ in three amino 
acids, PLF1 and MRP/PLF3 in two and PLF2 and MRP/PLF3 in only one (Connor et 
al., 1989). Comparison of the derived amino acid sequence of pifl and plf2 cDNAs to 
those derived from the available genomic coding sequence of plf42 and plf149 reveal 
that PLF1 may be a product of either plf42 or plf149 or both, while plf2 appears to be 
the product of a different mrp/pifgem (Linzer and Mordacq, 1987), which is yet to be 
cloned (Table 1). 
Figure 1. DNA sequence elements (consensus transcription factor binding motifs) 
located in the mrp/plf3 gene 5' upstream sequence 
Within the mrp/plf3 gene 5' upstream sequence (-1100 to +99) several transcription 
factor binding DNA consensus sequences occur. Some of these sequence locations 
are indicated in this figure. 
TIE, TGF-p inhibitory element (CCTTGGTGTCCAT)(-1004 to-995) 
Y, YY-1 core sequence (CCAT)(-995 to -992 and -683 to -680) 
YY1, well coserved YY1 (yin and yang) or F-Acti binding sequence (GTATGGT) 
(-929 to-923) 
GATA, erythroid consensus motif recognized by ail three GATA transcription factors 
(GATA1, 2 and 3) with high affinity (AGATAA)(-785 to -780) 
OCT, 7/8 identity to Octamer binding motif (TTTG^T)(-542 to -536, and -91 to -84, 
located on minus strand) 
SPH, 7/9 identity to SV40 Sphi sites; there are five such sites of which only two are 
indicated 
cGRE, composite glucocorticoid response element (GCTACTCACAGTATGATTT 
GTT)(-253 to-232) 
TPA-inducible element, (GTTTTAGTCAGAGCATGAACATGAGATGAAT)(-234 to 
-204); includes an API site (-231 to -225) and five bases of a second API site 
(-208 to-204) 
SRE, serum response element of hsp70 (GGGAAAA)(-101 to -95) 
AP2, 7/9 identity to AP2 binding site (GCCTGGGT)(+47 to +55) 
6 
GATA 
•51 +1 
TATATAA G. 
+ 20 
^TG 
+ 99 
Figure 2. Variations in the amino sequence derived from PLF1 and PLF2 cDNAs and 
from the coding sequence of/nrp/p/f3 
The proteins encoded by PLF1 and PLF2 cDNAs and mrp/plf3 gene coding sequence 
are represented diagrammatically as rectangular blocks. The numbers represent the 
position of amino acids that vary among PLF1, PLF2 and MRP/PLF3. The letters 
within the blocks represent their respective codon sequence while the letters outside 
indicate the name of the amino acid. The number 224 indicates the total number of 
amino acids in the unprocessed protein. The first 29 amino acids code for a signal 
peptide that is absent in the mature protein. 
PLF1 
Leu 
ifiUS 
Ser Thr Ser Leu 
tea act 
I I I I 
itii 
63 67 107 117 224 
Ser 
PLF2 
Ser Asn Ala Ser 
00 
Ser 
MRP/PLF3 H 
Ser Asn Ala Leu 
9 
Table 1. Cloned MRP/PLF genes, their 5' Upstream Sequences, Exons, 
Introns and cDNAs 
Gene 5' Upstream 
Sequence 
(bp) 
Exons/lntrons cDNA 
plf42 -1100 first exon and 300 
bpoffirstintron 
plf149 -1100 first exon and 300 
bpoffirstintron 
plf42 orplf149 PLFr 
Not available PLF2** 
mrp/plf3 -2000 entire genomic sequence 
(9.5 Kbp) that includes 
5 exons and 4 introns 
MRP/PLF3 
* from available sequence information it is concluded that PLF1 cDNA 
may be the product of either the plf42 or plf149 gene 
** the gene that encodes PLF2 cDNA has not been cloned 
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Basic Fibroblast Growtfi Factor 
Basic fibroblast growth factor (bPGF) also called FGF2 belongs to the FGF 
gene family that consists of eight other members in mammals. It has a basic pi (>9.0), 
an affinity for heparin like other members of this family ,and is eluted from heparin-
sepharose columns at 1.5 M NaCI (Esch et al., 1985). Basic FGF occurs in a variety 
of isoforms arising from alternative splicing (Zuniga Meijer Borja et al., 1992), by 
initiation of translation at non-AUG start sites (Quarto et al., 1991) and by 
posttranslational modifications. Bovine pituitary bFGF is a 146 amino acid protein with 
a molecular weight of 16.4 kDa (Esch et al., 1985) v\ i^le human placental bFGF has 
157 amino acids with a molecular weight of 17.5 kDa (Sommer et al., 1987). A high 
molecular weight bFGF (25 kDa) has been isolated from guinea pig brain (Moscatelli 
et al., 1987). Immunoprecipitation and western blot analyses from numerous cell lines 
reveal bFGF of molecular weights of 18, 22, 22.5 and 24 kDa (Rifkin and Moscatelli, 
1989). The biological roles of these bFGF variants remains unclear. Additional 
diversity appears to occur by posttranslational modifications such as methylation (of 
nuclear forms), phosphorylation (of all isoforms), ribosylation, and nucleotidylation 
(reviewed in Mason, 1994). 
Basic FGF is a ubiquitous growth factor found in all organs, solid tissues, 
tumors, and cultured cells examined (reviewed in Rifkin and Moscatelli, 1989) 
including the brain, corpus luteum, kidney adrenal glands, retina, monocytes, and 
macrophages (Baird et al., 1986). This growth factor displays a wide range of 
biological functions (reviewed by Rifkin and Moscatelli, 1989; Mason, 1994; and Slack, 
1994). It increases cell proliferation, promotes cell migration and is involved in 
neovascularization and wound repair. It is widely expressed during vertebrate 
11 
development and has been implicated In many development events. For instance, 
bFGF is involved in early specification of mesoderm in Xenopus (Amaya et al., 1993). 
Basic FGF stimulates the expression of plasminogen activator (Mignatti et al., 1989), 
interstitial and type I collagenase (Moscatelli et al., 1986), skeletal and smooth muscle 
a-actin, ^-myosin heavy chain and atrial natriuretic factor in cardiac myocytes (Parker 
et a!., 1992), decorin and type I collagen in normal and keloid fibroblasts (Tan et al., 
1993), and Xbra, MyoD and muscle actin in Xenopus animal-cap (MacNicol et al., 
1993). Cytoplasmic forms of bFGF increases expression of integrins pi, a5 and a6 
(reviewed in Mason, 1994). 
The mechanism(s) of signal transduction by FGFs is intriguing. Their signal 
transduction occurs through a family of transmembrane receptors that are tyrosine 
kinases. Four genes for FGF receptors (FGFR) are known. FGFRs generally have 
three extracellular immunoglobulin-like loops, a transmembrane domain and an 
intracellular tyrosine kinase domain. The activated FGFRs are autophosphorylated 
which stimulates the recnjitment of intracellular signalling molecules that frequently 
contain SH2 (Src homology 2) domains (Mason et al., 1994). bFGF signalling through 
the different FGFRs appear in some cases to invoke the Ras-Raf-MAP kinase pathway 
(MacNicol et al., 1993). FGFR directly interacts with phospholipase C-y (PLC^) and 
is also involved in the activation of She, an SH2 adaptor protein. Extracellular bFGF 
apart from binding to the FGFRs has also been reported to be translocated to the 
nucleus (Bouche et al., 1987; Baldinetal., 1990; Powell and Klagsbrun, 1991; Quarto 
et al., 1991; Dono and Zeller, 1994). It is therefore likely that bFGF may have specific 
functions in the nucleus apart from functioning through the stimulated tyrosine kinase 
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activity of its membrane receptors. It is possible that bFGF may have a direct role in 
regulating gene transcription as shown by Nakanishi et al. (1992) in a cell free in vitro 
transcription system. The different forms of bFGF generated are differentially 
distributed within the cells in which they are localized (Mason, 1994). The 18 kDa form 
is predominantly cytosolic while the 22-24 kDa forms are targeted to the nucleus. 
The expression of mrp/plf genes is regulated by bFGF in 3T3 cells. bFGF is 
expressed in the placenta (Gospodarowicz et al., 1985; Sommer et al., 1987; Gonzalez 
et a!., 1990; Hondermarck et al., 1990; Cattini et al., 1991; Ferriani et al., 1994) and 
because MRP/PLF is expressed in the giant trophoblast cells of murine placentae, it 
may be one of the targets for regulation by bFGF during murine development. 
Thesis Organization 
This thesis includes a general introduction to mitogen regulated protein/ 
proliferin and basic fibroblast growth factor, two papers to be submitted for publication 
and a general conclusions chapter. The papers have been presented in the form 
required by the specific journals they will be submitted to. Any references cited in the 
general introduction and general conclusions are included in the reference section that 
follows the general conclusions. 
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BASIC FIBROBLAST GROWTH FACTOR REGULATES MITOGEN REGULATED 
PROTEIN OR PROLIFERIN GENE EXPRESSION BY INCREASING THE RATE 
OF PROCESSING OF ITS HETEROGENOUS NUCLEAR RNA 
A paper to be submitted to the Journal, Molecular and Cellular Biology 
Manzoor All P.K. Mohideen and Marit Nilsen-Hamilton 
Molecular, Cellular and Developmental Biology Program, Department of 
Biochemistry and Biophysics, Iowa State University, Ames, lA 50011 
ABSTRACT 
Mitogen regulated protein or proliferin (MRP/PLF) is a secreted glycoprotein 
belonging to the prolactin/growth hormone gene superfamily and is expressed in the 
giant trophoblast cells of murine placentae. It stimulates proliferation of murine uterine 
cells and is considered to be a uterine growth factor. Basic fibroblast growth factor 
(bPGF) regulates the expression of mrp/plf genes in 3T3 cells. We demonstrate that 
of the several copies of mrp/plf genes in the murine genome, bPGF regulates the 
expression of only one, mrp/plf3, by transcriptional activation as evidenced by stable 
transfection of chloramphenicol acetyl transferase reporter gene plasmids. However, 
the mrp/plf gene that is nomially expressed in 3T3 cells in response to bFGF is 
regulated posttranscriptionally. Northern analyses following treatment of cells with 
cordycepin, an inhibitor of transcription, and pulse chase analyses of mRNA that was 
metabolically radiolabeled with ®P-P04, indicate that the MRP/PLF mRNA (PLF1) that 
is expressed in these cells is not regulated at turnover by this growth factor. 
Radiolabeled pulse chase assays of nuclear RNA demonstrated that bFGF increases, 
compared to the control, the rate at which the PLF1 heterogenous nuclear RNA 
(hnRNA) is processed in the nucleus. The increased processing of PLF1 hnRNA 
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accounts for the transient increase in the PLF1 mRNA upon bFGF addition to 3T3 
cells. This is the first report of a growth factor regulating gene expression by 
controlling hnRNA processing. 
INTRODUCTION 
Mitogen regulated protein (MRP) is a glycoprotein of 34 kd relative molecular 
weight which is secreted in vivo by the murine placental giant trophoblast cells during 
mid-gestation (1, 2, 3). This protein was first described by Nilsen-Hamilton et al. (4) 
as a protein whose expression by 3T3 cells was elevated upon addition of growth 
factors such as epidermal growth factor, fibroblast growth factor, or serum in the 
growth medium. Linzer and Nathans (5) isolated an mRNA from Balb/c 3T3 cells 
whose levels increased in growing cells. They called the encoded protein proliferin 
(PLF). Later studies revealed that both MRP and PLF were the same protein (6, 7). 
Therefore, in this paper MRP shall be referred to as MRP/PLF. 
It has been reported that there are four (8), five (9) or six (10) copies of the gene 
in the mouse genome. Two genomic DNA clones (designated plf42 and plf149) 
containing the first exon, 1.1 kb of 5'upstream sequence and 300 bp of the first intron 
(10) and a third genomic clone (called mrp/pifS) comprising the complete gene and a 
2000 bp 5'upstream sequence (9) have been isolated. pif42 and plf149 were obtained 
from a Balb/c mouse genomic library while mrp/plf3 from a Swiss mouse embryo 
fibroblast genomic library (ibid). Two complete MRP/PLF cDNA sequences called 
PLF1, from Balb/c 3T3 cells (5) and PLF2, from Balb/c mouse placenta (1) and a 
partial sequence of a third called, MRP/PLF3, from mouse BNL cells (6) have also 
been cloned. Comparison of the derived amino acid sequence of PLF1 and PLF2 with 
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those known for plf42 and plf149, indicates that PLF1 is the product of plf42 or plf149 
while PLF2, whose genomic sequences have yet to be cloned, appears to be the 
product of a different mrp/plf gene (10). The deduced amino acid sequence of the 
cDNAs, PLF1 and PLF2 and that of the coding sequence of MRP/PLF3 are almost 
identical; out of 224 amino acids PLF1 and PLF2 differ only in four and PLF1 and 
MRP/PLF3 only in three, one of the variant amino acids occurring in the signal peptide 
sequence; PLF2 and MRP/PLF3 vary in three amino acids which are part of the mature 
protein (9). 
MRP/PLF is a uterine growth factor that acts in midgestational murine 
development. Purified MRP/PLF enhances DNA synthesis in primary cultures of 
uterine cells derived from day 9 through 12 pregnant mice (11). PLF1 inhibits 
myogenic differentiation of C3H/10T1/2 cells (12). This activity is mediated by 
suppressing the level and/or activity of CArG-binding factor, which is a trans-acting 
factor that modulates the expression of multiple muscle-spedfic genes (13). MRP/PLF 
belongs to the prolactin/growth hormone gene family (5). It is recognized by at least 
two forms of receptors. When the protein t>ears mannose 6-phosphate it is recognized 
by the cation independent mannose 6-phosphate receptor (3). A specific MRP/PLF 
receptor is expressed by the mouse uterus (11), which seems to be a signal 
transducing receptor. MRP/PLF is expressed by the placenta and secreted into the 
maternal blood stream exhibiting a specific developmental profile, its level in the 
maternal serum peaking at day 11 of gestation and returning to basal levels between 
days 13 and 14 (1, 14a, 14b). A similar expression pattern is shared by placental 
lactogen I, which like MRP/PLF is a member of the prolactin/growth hormone gene 
family (15). GATA3, a developmentally regulated transcription factor shows a similar 
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expression pattern as placental lactogen I (16). GATA3 has also been shown to 
regulate the transcription of the placental lactogen promoter in transient transfection 
assays (ibid). Considering the different features of MRP/PLF and its relation to other 
biologically important molecules as outlined above, it is reasonable to speculate that 
MRP/PLF may play a significant role in mouse development. 
Mitogens such as serum, FGF, EGF (4), PDGF (5), and PMA (17) increase the 
expression of MRP/PLF in 3T3 cells. Of all these growth factors bFGF (FGFII) 
increases MRP/PLF production the most (unpublished data). bFGF has been identified 
in almost all organs, solid tissues, tumors and cultured cells examined (18) including 
the placenta which is the organ that expresses MRP/PLF in vivo. This leads to the 
hypothesis that bFGF may be among the regulators of mrp/p/^ expression. Although 
several aspects of the bFGF signal transduction pathway has been elucidated 
(reviewed in 19), it is not clear how it acts to control the expression of specific genes. 
Because, mrp/plf is clearly regulated by bFGF in 3T3 cells, we have performed 
experiments to determine at which level(s) this growth factor exerts its action. In this 
study we show that bFGF increases the levels of MRP/PLF mRNA in 3T3 cells. This 
increase is not due to transcriptional activation but is due to regulation of processing 
of mrp/p/^ heteronuclear RNA (hnRNA). 
MATERIALS AND METHODS 
Metabolic Labeling of cells with ^S-Methionine 
Swiss 3T3 cells were used in all experiments. The cells were plated at a density 
of 1(/ cells/cm^ on multi-well plastic dishes in DME (Dulbecco-Vogt modified Eagle's) 
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medium containing 10% calf semm and incubated at 37°C in an humidified 
atmosphere containing 12% CO2. Two to three days later when the cells were 50% 
confluent, 5 ng/ml bFGF with 0.005% BSA was added to the condition medium. 
Control cells were treated with 0.005% BSA. The cells were incubated for 18 h, 
followed by labeling with *S-methionine (100-125 ^Ci/ml and 1100 to 1250 Ci/mmol) 
or ^-trans label (ICN) (100-125 |jCi/ml and 1000 Ci/ mmol). At the end of this period 
the medium was collected, the cells were lysed with NP40 lysis buffer, nuclei and post-
nuclear supematants were separated by centrifugation. Aliquots of the post-nuclear 
supernatants were used to measure the acid-insoluble cpms which were used for 
correcting variations in total protein synthesis. The medium was resolved by 
electrophoresis on an SDS-polyacrylamide gradient gel (7.5 to 15%) and prepared for 
fluorography as described elsewhere (20). The fluororadiographs were exposed to x-
ray film (X-OMAT AR; Eastman Kodak Go.,) for varying periods and the extents of 
exposure were quantified for specific proteins using a scanning densitometer (Zieneh, 
Model SL-504-XL, Biomed instruments. Inc.) and with film exposures that were within 
the linear range of response as determined from calibrated samples. 
Nuclear Run-on in vitro Transcription Assay 
Nuclei were isolated from cells treated with bFGF as described under "metabolic 
labeling" and the nuclear run-on transcription assay was performed according to the 
method of Greenberg (21). The transcription reaction (400 pi) containing 20% 
glycerol, 5 mM MgClj, 0.05 mM EDTA, 150 mM KCI, 2.5 mM dithiothreitol, 0.5 mM 
ATP, 0.5 mM TTP, 0.5 mM GTP, 120 to 160 pCi [^PJUTP (3000 Ci/mmol), and 30 mM 
Tris, pH 8.0 was incubated for 30 min at 30°C. To the transcription reaction 2.1 ml of 
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GIT solution (4 M guanidinium isothiocyanate, 105 mM 2-mercaptoethanol, and 25 mM 
sodium acetate, pH 6.0) was added and the solution was briefly vortexed. The newly 
transcribed RNA was isolated by layering the GIT extract over an equal volume of 
cesium chloride solution (5.7 M cesium chloride and 25 mM sodium acetate, pH 6.0) 
and centrifuging at 140,000g in a swinging bucket rotor for 18 h. The RNA pellet was 
dissolved in diethyl pyrocarbonate-treated water and ethanol precipitated. RNA was 
quantified by determining the acid-insoluble cpm using ascending thin layer 
chromatography to separate the acid-soluble from acid-insoluble material. The 
labelled RNA (1.4x10° to 17x10° acid-insoluble cpm/ml) was hybridized to denatured 
and linearized cDNA probes (5 |jg cDNA/slot) that had been blotted to nylon 
membranes (Zeta Probe, Biorad), The probes used in these studies were: pRSVPLFI 
containing the MRP/PLF-1 cDNA insert (12), pDF8 containing the rat 18S RNA cDNA 
(22), pMGAP containing the glyceraldeyde-3-phosphate dehydrogenase cDNA (23a), 
pFN containing the cDNAfor fibronectin, p65D5 containing the cDNA for a rat mRNA 
whose levels remain unalterd by growth factor treatments in rat2A cells. The plasmid 
cloning vectors pBR322 and pBluescript (Stratagene) were used here as controls for 
background values. Hybridization was carried out in 40% deionized formamide, 4x 
SSPE (0.6 M NaCI, 5 mM EDTA, 40 mM NaH2P04, pH 7.4), 7% SDS, 1% PEG 
(20000), 0.5% non-fat milk, 100 ug/ml wheat germ tRNA and 1.4x10® to 17x10® acid-
insoluble cpms of labelled newly-transcribed RNA. Following hybridization, the blots 
were washed with 0.5% SSC, 0.2% SDS for 15 min, twice at 24''C and in 0.2% SSC, 
0.2% SDS twice at 48°C. The blots were exposed to a storage PhosphorScreen 
(Molecular Dyanmics) and the images were analyzed on a Phosphorlmager using the 
ImageQuant software (Molecular Dynamics). 
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RNA Isolation, Gel Electrophoresis, Northern Blotting and Hybridization 
The cells from which total RNA was isolated were grown under the same 
conditions as the cells for the nuclear run-on transcription assay. After the specified 
periods of stimulation with bFGF the cells were washed once with TBS (68 (jM CaClj 
and 49 mM MgClj, 140 mM NaCI, 5 mM KCI, 0.4 mM Na2HP04. 25 mM Tris, pH 7.5). 
The cells were solubilized in GIT buffer and total RNA was isolated by centrifugation 
through a cesium chloride cushion at 140,000gfor 18 h. Total RNA samples (15 jjg) 
were electrophoresed in denaturing gels containing 1% agarose, 2% fonnaldehyde, 
10 mM EDTA, 200 mM MOPS (3-(N-morpholino)propane sulphuric acid), 50 mM 
sodium acetate, pH 7.0. The gels were blotted onto nylon membranes (either Zeta 
Probe (Biorad) or Biotrans (ICN)) by the capillary method following the protocol 
supplied by the manufacturer. The transferred RNA was fixed to the membranes by 
baking at 80°C. The northern blots were sequentially probed for MRP/PLF, 
glyceraldehyde-3-phosphate-dehydrogenase (G3PDH) and 18S RNA. Probes used 
in these studies were the cDNA inserts from the respective plasmids. Probes were 
made by random priming using the Multiprime Labelling Kit (Amersham) following the 
supplier's protocol. Northern blots were hybridized at 48°C in 40% deionized 
formamide, 4xSSPE, 7% SDS, 1% PEG (20000), 100 pg/ml salmon sperm DNA, 100 
|jg/ml wheat germ tRNA, and 1 % NP40. Following hybridization the blots were washed 
twice sequentially at 24''C with 0.5% SSC and 0.2% SDS for 15 min and at 48°C with 
0.2% SSC and 0.2% SDS. The blots were exposed to X-ray film (X-OMAT AR; 
Eastman Kodak Co.,) for varying periods and the autoradiograms were quantified 
using a scanning densitometer (Zieneh, Biomed Instruments, Inc.) and with film 
exposures that were within the linear range of response as determined by calibrated 
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exposures to known amounts of ^P. The values for MRP/PLF were corrected to those 
of G3PDH and 18S RNA. The blots were also exposed to PhosphorScreen (Molecular 
Dynamics) and the image was analyzed on a Phosphorlmager using the ImageQuant 
software (Molecular Dynamics). 
RNA Decay Experiments 
Using cordvceoin as inhibitor of transcription 
3T3 cells were cultured in a similar manner as for the nuclear run-on 
experiments. When the cells were 50-60% confluent, bFGF (5 ng/ml) with BSA 
(0.005%) or BSA alone was added to the medium. The cells were then incubated for 
12 to 14 h at the end of which period, the transcription inhibitor, cordycepin (15 Mg/ml) 
was added to the medium to both control and bFGF-treated cells. The cells were 
incubated for a further periods of 0 to 10 h. At varying periods as indicated, following 
cordycepin administration, the cells were solubilized in GIT buffer and total RNA was 
isolated, electrophoresed, blotted, hybridized to probes (MRP/PLF, G3PDH, and 18S 
RNA), and quantified as described above. For each experiment, the corrected values 
for the relative amounts of MRP/PLF mRNA are expressed as a proportion of the 
value obtained just before the addition of cordycepin (time zero). 
Pulse Chase 
3T3 cells were first plated and cultured as for the nuclear run-on experiment 
outlined above. When the cells were 50-60% confluent the medium was replaced by 
phosphate-free DME medium (31093-016, GIBCO/BRL), containing 10 Units/ml each 
of penicillin and streptomycin (GIBCO/BRL), 1% dialyzed bovine calf serum, (^^P)-
ortho-phosphate (100 pCi/ml, NEX-011, Dupont/NEN or 64051, ICN), 0.005% BSA with 
or without 5 ng/ml bFGF. The cells were labelled for 12 or 14 h. After the labelling 
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period the cells were rinsed twice with TBS and then conditioned medium obtained 
from cells that were grown in parallel in DME medium containing 10% bovine calf 
semm, 15 \iglm\ cordycepin, and excess of non-radioactive phosphate was added to 
the labelled cells. In the case of bFGF-treated cells additional bFGF (5 ng/ml) was 
also added to the medium. At the indicated periods after the chase, the cells were 
solubilized and total RNA was isolated as indicated above. For the isolation of nuclear 
RNA, nuclei were first isolated as described under "metabolic labelling" and lysed with 
GIT buffer. RNA was extracted as before using cesium chloride gradient 
ultracenrifugation. Equal amounts of labelled RNAs (4-10 x 10° TCA precipitable 
cpm/ml) were hybridized to an excess of non-radioactive cDNA probes (MRP/PLF, 
G3PDH, 18S RNA, pBR322, and pRSV2) which had been blotted onto Biotrans 
membrane (ICN) using the BIO-DOT Miaofiltration Apparatus (Biorad). The conditions 
for hybridization and post-hybridization washes were as described for Northern blots. 
The blots were exposed to a PhosphorScreen (Molecular Dynamics) and the images 
were analyzed using the Phosphor Imager and the ImageQuant software (Molecular 
Dynamics). The results for MRP/PLF were corrected by subtracting the values 
obtained for hybridization to the vector, pRSV2 and those for G3PDH and 18S RNA 
to pBR322. The corrected values are expressed as a proportion of the values 
obtained just before starting the chase (zero time). 
RT-PCR and Restriction Analysis of PGR Products 
Total RNA from bFGF-treated and control cells was reverse transcribed to 
synthesize the first strand cDNA in a 25 |j| reaction mix. The reverse transcription (RT) 
reaction mixture consisted of 2 pg total RNA, 50 mM KCI, 0.1% triton X-100, 6.0 mM 
MgCl2,200 mM dNTPs, 10 mM dithiothreitol, 300 Units M-MLV reverse transcriptase 
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(RNase H minus) (Promega), 10 Units ribonuclease inhibitor (RNasin, Promega), 40 
MM of primer. BF1 (5'ACT CAC TAG ATC GTC CAG AGG 3'), 50 mM Tris CI, pH 9.0. 
The reaction was carried out at 37®C for 2 h. The products of the reverse transcription 
reaction were used for PGR. Each PGR reaction mixture (100 pi total volume) 
included: 10 pi RT reaction mix, 50 mM KGI, 1.5 mM MgGlj, 0.15 Triton X-100,1 mM 
dithiothreitol, 200 ul dNTPs, 40 pM primer, BF1,40 pM primer, BF2 (5' TCT AAG GTG 
TGT GGG GTC AGA 3'), 2.5 Units Taq Polymerase (Promega), 14 mM Tris.GI, pH 9.0. 
The PGR primers were designed to amplify a 168 bp sequence of the MRP/PLF RNA. 
Reactants were heated in a Hybaid Thermal cycler to 94''G for 7 min, cooled to 50°G 
for 2 min, heated to 72°G for 3 min and then cycled 38 times for 1 min at 94°G, for 2 
min at 50°G and for 3 min at 72°G with a final cycle of 94°G for 1 min, 50°G for 2 min 
and 72''G for 7 min. After the PGR was complete, each reaction was extracted once 
with isoamyl alcohol to remove the mineral oil overlay. As positive controls for the 
PGR, two MRP/PLF cDNAs, plf-1 and plf2 inserted into the plasmids, pRSVPLFI and 
pRSVplf2, respectively (12), were amplified. As a negative control RT-PGR was 
performed with distilled water in lieu of total RNA as sample. PGR products were 
precipitated by ethanol and the pellet dried and resuspended in 20 pi water. The 
cDNA was digested with the restriction enzymes, BstXI and Fnu4HI and the restriction 
fragments were resolved by elecrophoresis through an 8% polyacrylamide or 2 % 
agarose gel. 
23 
RESULTS 
bFGF Does Not Stimulate the Expression of all Copies of the m/p/ptf Genes in 
3T3 cells 
To determine which of the mrp/plf genes are expressed in 3T3 cells in response 
to bFGF we have developed an RT-PCR assay which is based on the few differences 
in sequence among the three known RNAs. Total RNA was isolated from untreated 
and bFGF-treated cells and reverse transcribed. The first strand cDNAs were used 
as templates for PGR along with two primers, BF1 and BF2. These primers ensured 
the specific amplification of a 168 bp segment of the mrp/plf transcripts. Within this 
fragment are variations in two bases that have given rise to two specific restriction 
enzyme sites using which the gene from which the transcripts arose can be identified. 
The PLF1 transcript has a BstXI site, the plf2 transcript has a Fnu4HI site and the 
mrp/plf3 transcript has both these sites (Figure 1). The transcripts were restricted with 
both enzymes in a double digestion reaction and the products were resolved on 2% 
agarose gel (Figure 2). Two restriction fragments (129 and 39 bp long) were 
observed. This corresponds to what is expected from PLF1 transcripts (Figure 1). 
From sequence information that is available PLF1 transcripts may be encoded by the 
plf42 or the plf149 genes thereby suggesting that plf42 or plf149 or both these genes 
may be expressed in these cells in response to bFGF while mrp/plf3 is not. Both 
bFGF-treated and untreated control cells express either the plf42 or plf149 or both 
genes but not the mrp/p/f3 gene. 
P^42 and ptf'/49 Genes are Not Transcriptionally Activated by bFGF 
Nuclear run-on in vitro transcription assays were performed to determine if 
bFGF activates the transcription of the mrp/plf genes in 3T3 cells. Cells were treated 
with bFGF and at different time periods (4 to 14 h), nuclei were isolated from harvested 
Figure 1. The RT-PCR/Restriction analyses strategy used to identify the MRP/PLF 
genes expressed in 3T3 cells in response to bFGF. 
Total RNA from cells treated with bFGF is first reverse transcribed. The first strand 
cDNAs are then used as templates in a PGR reaction in which primers BF1 and BF2 
ensures the amplification of a specific 168 bp segment of the MRP/PLF transcript, 
which is shown here. The PLF1 fragment has a BstXI site, PLF2 has an Fnu4HI site 
and MRP/PLF3 has both these sites. Upon double digestion with both the restriction 
enzymes these amplified sequences form specific sized fragments which can be 
resolved using polyacrylamide or agarose gel eletrophoresis thereby enabling 
identification of the origin of the transcripts. 
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cDNA 
BstXI 
Restriction 
fragments 
<bp) 
PLF1 129,39 
|Fnu4H1 
PLF2 101,67 
1 1  
MRP/PLF3 2®' 
Figure 2. Only PLF1 is expressed in 3T3 cells 
The 168 bp fragment obtained by RT-PCR of the total RNA from bFGF-treated 3T3 
cells using the strategy described in Figure 1 was digested with both BstXI and Fnu4HI 
restriction enzymes. The products of the reaction were then resolved on a 2% agarose 
gel to reveal the different restriction fragments obtained (lanes 3T3). Lanes PLF1 and 
PLF2 indicate the PGR amplified fragments obtained by using plasmids carnrying the 
PLF1 and PLF2 cDNA respectively. PLF1+PLF2 lanes show the PGR products 
obtained when both the plasmids were included in the reaction. U- indicates uncut. 
B= BstXI, F= Fnu4HI. 
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cells and nuclear run-on in vitro transcription reactions were performed using ^P-UTP 
to label the run-on transcripts. RNA was isolated and hybridized cDNA probes (which 
included PLF1 cDNA) immobilized on nylon membranes. Membranes were analyzed 
on a Phosphorlmager. Results indicate that bFGF does not increase the transcription 
of the expressed mrp/plf genes (Figure 3). 
In order to confirm these results, -1100 to -^5 bases of the plf42, plf149 and 
mrp/plfS promoter sequences were ligated to the CAT reporter gene in the pCAT Basic 
vector. These mrp/pif-CAT reporter plasmids were then transfected into 3T3 cells. 
Pooled, stably transfected cells were treated with bFGF for 24 to 38 h. The cells were 
harvested and CAT activity was measured in the cell lysates. Results obtained (Figure 
4) show that plf42 and PLF149 promoter sequences were not stimulated by bFGF. 
However, the mrp/plf3 promoter sequence was activated by almost two-fold by this 
growth factor. The observation that only the PLF1 transcript, which could arise from 
the plf42 or pif149 genes or both is expressed in these cells and mrp/plf3 is not and 
that mrp/plf3 is the only gene that is transcriptionally activated (as observed in CAT 
reporter gene assays) suggests that the different members of the same gene family are 
regulated by different mechanisms. 
Basic FGF Stimulates an Increase in PLF1 mRNA 
Total RNA was isolated from 3T3 cells that were or were not treated with bFGF 
for different periods of time ranging from 0 to 24 h. After being resolved through a 
denaturing agarose gel, the RNA was blotted to nylon membranes and then hybridized 
to ^P-labeled PLF1 probe. Values were normalized to the levels of 18S RNA. It was 
found that bFGF increased the levels of PLF1 mRNA (Figure 5) with the peak value 
Figure 3. Tlie Endogenous MRP/PLF Genes are Not Transcriptionally Activated by 
bFGF 
3T3 cells were treated with bFGF (5 ng/ml) for 4 to 16 h. At the end of the indicated 
periods cells were harvested and nuclei isolated. Nuclear run-on in vitro transcription 
reaction was performed and RNA was isolated as indicated in Materials and Methods. 
The labeled RNA was then hybridized to immobilized probes blotted on to nylon 
membranes. The hybridized membranes were exposed to a PhosphorScreen and 
bands were scanned using a Phosphorimager and quantified using the ImageQuant 
software (Molecular Dynamics). The values for PLF1, the mrp/plf-speciTic probe was 
normalized to those of p65D5,18s RNA and G3PDH. The figure shows the values in 
terms of arbitrary units as normalized to p65D5. Bar heights represent mean ± SD of 
four independent experiments. 
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Figure 4. mrp/plf3 Gene promoter is Transcriptionally Activated in CAT Reporter Gene 
Transfection Assays 
The 5' upstream sequences (-1100 to +65 bp) of mrp/plf3, plf42 and plf149 genes were 
ligated upstream of CAT reporter gene in pCAT Basic vector and transfected into 3T3 
cells. Pools of stably transfected cells were then treated with bFGF (5 ng/ml) for 24 
to 38 h and CAT activity was analyzed in the cell lysates. 
(A) The histogram shows the actual CAT activity values obtained in a representative 
experiment. without bFGF; +•, with bFGF 
(B) Indicates the mean CAT activity in terms of fold increase of bFGF-treated over that 
of control ± standard deviation. 
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Figure 5. bFGF Increases the PLF1 mRNA Levels in 3T3 Cells 
Figure shows the temporal profile of PLF1 mRNA in control and bFGF-treated cells (5 
ng/ml). Cells were treated with bFGF and incubated for a duration of up to 22 h. At 
the indicated times total RNA was isolated as described in Materials and Methods. 
RNA was blotted and hybridized first to PLF1 probe, stripped and hybridized to 18S 
RNA probe. The blots were then exposed to Kodak X-Omat film and the resulting 
autoradiograph was analyzed by scanning using a densitometer. The values on the 
Y-axis are the intensities of the PLF1 band normalized to that of the corresponding 
18S RNA bands. Diamonds, control; squares,+bFGF. 
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occurring after 16 h of stimulation. 
Basic FGF Does Not Stabilize PLF1 mRNA 
The observation that bFGF increases the level of PLF1 mRNA but does not 
increase its transcription rate suggested that this growth factor might be regulating the 
expression of plf42 or plf149 or both these genes by mechanisms other than 
transcn'ptional activation. One possible mechanism may be that this growth factor acts 
in a way to stabilize the basal PLF1 mRNA thereby resulting in transient increase in 
the message followed by a decline. To test this hypothesis two kinds of experiments 
were performed: 1) using cordycepin as an inhibitor of transcription and 2) pulse chase 
experiments. 
Cordycepin as an Inhibitor of Transcription 
Cells were incubated with bFGF for 12 to 14 h. Control cells were not treated 
with the growth factor. At the end of this period the transcription inhibitor, cordycepin, 
was added to the medium of both control and bFGF-treated cells. The cells were 
incubated for an additional period of 0 to 10 h. At varying periods following cordycepin 
addition, total RNA was isolated and Northern hybridzation analyses were performed. 
The PLF1 mRNA levels in both bFGF-treated and control cells remained relatively 
stable over the 5h period analyzed (Figure 6a). We also observed similar results with 
the tumover rate of IBS and G3PDH RNA which were analyzed as controls (Figure 6b 
and c). It has been reported that the half life of G3PDH is about 24 h (23b). In our 
studies we observed stabilization of these messages which could be attributed to 
secondary effects or artifacts resulting from prolonged exposure to cordycepin. In 
order to evaluate the half lives without the use of drugs we performed pulse chase 
analyses using (^P)-ortho-phosphate. 
Figure 6. Determination of Half Life of PLF1 mRNA Using Cordycepin as an Inhibitor 
of Transcription 
Cells were treated with bFGF (5 ng/ml) for 12 to 14 h. Control cells did not receive any 
bFGF. At the end of this period cordycepin (15 |ig/ml) was added to both control and 
bFGF-treated cells. The cells were incubated for a further period of 0 to 10 h. At the 
times indicated following addition of cordycepin cells were harvested, total RNA 
extracted, blotted and hybridized sequentially to radiolabeled probes. The blots were 
then exposed to Kodak X-Omat film and the autoradiographs were quantified using a 
densitometer. a)PLF1 -PLF1 probe; b) G3PDH -glyceraldehyde-3-phosphate 
dehydrogenase probe; and c) 18S -18S RNA probe. Values on the Y-axis are 
logarithmic values of fraction remaining compared to amount present at the time of 
cordycepin addition. This figure shows the values (mean ± SD) obtained with a 
maximum of 5 h treatment with cordycepin from two independent experiments. Open 
circles, control; closed squares, bFGF. 
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Pulse Chase Analyses 
Cells were grown in phosphate-free DMEM containing 1% dialyzed bovine calf 
semm, (®P)-ortho-phosphate (100 mCi/ml) and with or without bFGF. The cells were 
incubated for 12 to 14 h following which the medium was replaced respectively with 
control and bFGF-treated conditioned medium containing excess cold phosphates and 
the label was chased for a period of 0 to 32 h. Total RNA was isolated and hybridized 
to immobilized probes. The blots were analyzed using a Phosphorlmager. The half 
life of PLF1 in control cells was infinite within the scope of the experiment and that of 
bFGF-treated cells was 23 h (Figure 7a). The half lives of G3PDH and 18S RNA in 
both control and bFGF-treated cells were 27 h and 33 h respectively (Figure 7 b and 
c). The half life of PLF1 was much lower in bFGF-treated cells than in control cells 
thereby suggesting that this growth factor may not stabilize PLF1 mRNA but may exert 
a different type of regulatory control. One likely point of control could be to regulate 
processing of the PLF1 heterogenous nuclear RNA. This possibility was tested by 
performing pulse diase experiments in whidi bFGF incubation was for 6 h followed by 
a chase period of 0 to 80 minutes at the end of which time periods nuclear RNA was 
isolated and northern hybridzations to probes immobilized on nylon membranes were 
perfomaed. To detect PLF1 hnRNA, intron 2 from mrp/plf3 was used as probe. During 
the chase periods the medium also contained cordycepin to prevent contribution of 
new RNA to the hnRNA pool during this period. Results from these experiments are 
presented in Figure 8. In bFGF treated cells the PLF1 hnRNA appears to decline 
rapidly during the first 10 min following which the decline is slower vi^ iile in control cells 
the rate of decline is slow over the entire period (Figure 8). The half life of PLF1 
hnRNA in bFGF treated cells is 6.7 min while it is 53 min in control cells. However, the 
Figure 7. Determination of the Half Life of PLF1 mRNA With Pulse Chase Analyses 
Cells were first grown in phosphate-free DMEM containing 1% dialyzed bovine calf 
serum,[^P]-ortho-phosphate and with or without bFGF (5 ng/ml). After being labeled 
for 12 to 14 h, the labeling medium was replaced respectively with bFGF-treated or 
control conditioned medium containing excess non-radioactive phosphates. At the 
indicated periods after the chase, RNA was isolated and hybridized to cDNA probes 
immobilized on nylon membranes. The blots were exposed to PhosphorScreens and 
signals were scanned using a Phosphorlmager and quantified using the ImageQuant 
software (Molecular Dynamics), a) PLF1-PLF1 probe; b) G3PDH -glyceraldehyde-3-
phosphate dehydrogenase probe; and c) 18S -18S RNA probe. Values (mean ± SD) 
on the Y-axis are logarithmic values effraction remaining compared to amount present 
at the beginning of the chase. Open circles, control; closed squares, bFGF. 
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Figures. Turnover of PLF1 hnRNA 
Cells were first grown in phosphate-free DMEM containing 1% dialyzed bovine calf 
serum, [^P]-ortho-phosphate and with or without bPGF (5 ng/ml). The cells were 
labeled for 6 h, after which the labeling medium was replaced respectively with bFGF-
treated or control conditioned medium containing excess non-radioactive phosphates. 
At the indicated periods after the chase, RNA was isolated from the nuclei and 
hybridized to cDNA probes immobilized on nylon membranes. The probe used for 
PLF1 hnRNA was intron 2 from mrp/plf3 gene. The blots were quantified using a 
Phosphorlmager and ImageQuant software (Molecular Dynamics). The chase was 
performed for 80 min; however the graph depicts values obtained during the first 10 
min showing the rapid decline in bFGF-treated cells. For each time point the values 
obtained from two independent experiments are shown; the graph is based on the 
average value. Open triangles, control; closed squares, bPGF. 
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18S RNA exhibited a steady profile in both control and bFGF stimulated cells (Figure 
9) thereby suggesting that the effect of bFGF was specific for PLF1 hnRNA. 
DISCUSSION 
bFGF stimulates the expression of MRP/PLF protein in 3T3 cells (5). This study 
shows that the MRP/PLF expressed in these cells corresponds to the form derived 
from the PLF1 cDNA. This cDNA is coded by either plf42 or pif 149 genes (5). 
Therefore, of the several genes that encode MRP/PLF, bFGF can specifically regulate 
the expression of one specific gene(s). 
The stimulation of mrp/plf gene expression is not due to transcriptional 
activation of the p^42 or plf149 genes. This is confirmed by two lines of experiments: 
nuclear run-off in vitro transcription assays and stable transfection of promoter-CAT 
reporter fusion plasmids. Stable transfection results, however, also indicate that the 
third mrp/f^gene, mrp/plf3 is capable of being tmscriptionally activated by bFGF while 
its endogenous counterpart is not regulated by this growth factor. 
mrp/plf gene expression in 3T3 cells is regulated posttranscriptionally. 
Posttranscriptionally, a gene can be regulated at various points: processing and 
stability of heterogenous nuclear RNA (hn RNA); polyadenylation; transport of 
mRNAfrom the nucleus to the cytoplasm; rate of mRNA turnover; translation; and 
posttranslational events. Many eukaryotic genes have been known to be regulated at 
turnover (reviewed in 24, 25). We tested this possibility using cordycepin as an 
* 
inhibitor of transcription. Seeley et al. (26) reported using 100 ^.g/ml of cordycepin in 
their efforts to detemiine the decay rate of oat phytochrome mRNA while 15 ^g/ml was 
Figures. Turnover of 18S nuclear RNA 
This figure depicts the values obtained for 18S RNA in the same experiments as in 
Figure 8. The values obtained during the first 10 min of the 80 min chase are shown. 
Values on the Y-axis are logarithmic values of fraction remaining compared to amount 
present at the beginning of the chase. For each time point values obtained from two 
independent experiments are shown; the graph is based on the average value. Open 
triangles, control; closed squares, bFGF. 
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used by Chuang (27a) to determine the half life of plasminogen activator inhibitor-1 
mRNA in mink lung CCL64 cells. Weusedcordycepinat15^g/ml in our studies. We 
obsen^ed PLF1 mRNA was stable in both bPGF-treated and untreated cells during the 
period analyzed. Moreover, G3PDH mRNA and 18S RNA were also stable and their 
half life values were higher than what has been reported, suggesting that Cordycepin, 
tseing a metabolic inhibitor, may exert secondary influences that result in stablization 
of mRNAs. In this investigation, we did not use actinomycin D, another inhibitor of 
transcription that has been widely used in mRNA turnover studies because it has been 
reported to have stablization effects on mRNA as well (27a,b). Therefore, this 
approach was not pursued further. Instead, pulse chase experiments using ^P-P04 
were performed. 
Pulse chase experiments with ^P-P04 indicated that mrp/p/f expression is not 
regulated at turnover. The half life of G3PDH mRNA and 18S RNA in control and 
bPGF-treated cells were identical indicating that the effect of bPGF was specific for 
mrp/plf. The steady state level of mRNA is a function of the rate of synthesis and the 
rate of degradation. In control cells the PLF1 mRNA remained at the same levels 
during the period of the chase suggesting that it was very stable. However, in bPGF-
treated cells, the levels showed a decline with a half life 23 h. if bPGP had an effect 
on PLF1 mRNA turnover we should have observed, contrary to our actual observation, 
a rapid decline of the message in control cells and a slower decline in bPGP-
stimulated cells. The shorter half life of PLF1 mRNA in bPGF-stimulated cells 
compared to control cells may be related to the rapid decline in PLF1 mRNA after 
attaining its peak in bPGF-stimulated cells. Many of the genes (granulocyte-
macrophage colony stimulating factor (28); lymhpokine (29); c-myc (30, 31); interferon-
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Y, interleukin-3, v-myc and c-fos (32) whose expression have been known to be 
controlled at the level of mRNA turnover have a destabilization sequence, the ARE (A-
U rich element) in the 3' untranslated region (3' UTR) of their mRNA. The ARE does 
not occur in the 3' UTR of the MRP/PLF mRNAs. It is therefore clear, that the increase 
in PLF1 mRNA upon bFGF treatment was due to factors other than mRNA turnover. 
There is growing evidence that suggests regulation of gene expression can also 
occur at the level of hnRNA by control of stability, processing, polyadenylation and exit 
of mRNA to the cytoplasm. The inhibition of expression of class I transplantation 
antigens of the major histocompatibility complex in human adenovirus 12 tranformed 
cells is attributed to a posttranscriptional process ocurring within the nucleus (33); the 
increase in thymidine kinase (TK) mRNA at the Gi-S boundary in cycling Balb/c 3T3 
cells is the result of a dramatic alteration in the processing of the TK hnRNA (34); the 
accumulation of Xenopus ribosomal protein L1 mRNA is controlled at the level of 
splicing and hnRNA turnover (35); transcriptional and posttranscriptional events in the 
nucleus account for the stimulation of T-cell receptor-a and -p mRNA in SL12 cells 
(36); dihydrofolate gene expression in mouse cells is regulated by stabilization of 
hnRNA (37). The importance of efficient processing of primary transcripts to generate 
mature mRNA is reflected in the regulation of c-myc expression in HL60 cells (38): in 
proliferating HL60 cells the increase in c-MYC mRNA levels was attributed to 
stimulation of transcription and processing of its hnRNA; however, in terminally 
differentiated HL60 cells c-MYC mRNA levels decreased as a result of decline in its 
hnRNA processing. Our studies show that bFGF stimulates an increase in PLF1 
mRNA by posttransccriptional regulation at the nuclear level. PLF1 hnRNA declines 
gradually in control cells while in bFGF stimulated cells it exhibits a rapid decline in the 
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first 10 min. The probe used in these experiment was the intron 2 probe form mrp/plf3 
gene so that only hnRNA is detected. Growth factors, including bFGF are known to 
stimulate an increase in the level of nucleotides. In order to exclude incorporation of 
labeled nucleotides into newly transcribed RNA during the pulse chase, cordycepin 
was included in the chase medium. The rapid decline observed in bFGF stimulated 
cells could be due to: first, a rapid destabilization/degradation of the hnRNA; second, 
rapid processing of the hnRNA into mRNA; third, transport of mRNA to the cytoplasm. 
The first possibility can be excluded because as a result of bFGF stimulation there is 
an increase in the PLF1 mRNA If the PLF1 hnRNA had been degraded we should not 
see this increase. Proper RNA processing is generally a prerequisite for mRNA export 
(reviewed in 39). Goldfarb and Michaud (40) suggest that the nucleus may be able to 
assess the translatability of an mRNA and modulate its export accordingly. It is 
therefore most likely that bFGF increases the processing of PLF1 hnRNA (half life 7 
min) and the resulting PLF1 mRNA is rapidly translocated to the cytoplasm. The half 
life of hnRNA in control cells is 53 min indicating slow processing and/or slower 
transport to the cytoplasm. Malyankar et al. (41) have observed that in primary mouse 
embryo fibroblasts, MRP/PLF hnRNA is degraded in the nucleus while in 3T3 cells the 
transcripts are processed and mature mRNA is observed in the cytoplasm. This 
suggests that primary cells lack certain factor(s) that enable complete processing of 
MRP/PLF hnRNA. Immortalized cells may possess these factor(s) that enable 
complete processing and subsequent exit to the cytoplasm. It is conceivable that 
bFGF stimulation provides these factors either by activation of preexisting factors or 
by stimulating synthesis of new ones. 
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THE BASIC FIBROBLAST GROWTH FACTOR RESPONSE ELEMENT IN THE 
MRP/PLF3 GENE PROMOTER IS A GENERAL MITOGEN RESPONSE ELEMENT 
A paper to be submitted to the journal, Cell 
Manzoor-Ali P.K. Mohideen and Marit Nilsen-Hamilton 
Molecular, Cellular and Developmental Biology Program, Department of 
Biochemistry and Biophysics, Iowa State University, Ames, lA 50011 
Summary 
Basic fibroblast growth factor (bPGF) enhances the expression of the mitogen 
regulated protein/proliferin {mrp/plf) gene, which encodes a murine uterine growth 
factor belonging to the prolactin/growth hormone gene superfamily. We demonstrate 
that of the three mrp/plf gene promoters {mrp/plf3, plf42 and plf149) analyzed, only 
one, mqVplfS, is transcriptionally activated by bFGF although these promoters are over 
96 % identical. We have identified a 10 bp long bFGF response element (FRE) in the 
mrp/plf3 promoter that specifically binds nuclear factors from bFGF-stimulated 3T3 
cells. The corresponding sequences from plf42 and plf149 promoters do not exhibit 
such binding. The nuclear factors recognized by the FRE do not include the API 
compex. The FRE competes for factors in vivo as indicated by in vivo competition 
experiments. Nuclear factors from cells stimulated by other mitogens such as 
epidennal growth factor, platelet-derived growth factor-aa and phorbol myristate 
acetate are also recognized by the FRE suggesting that this response element may 
be a general mitogen response element. 
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Introduction 
Mitogen regulated protein (MRP/PLF; also called proliferin) is a 34 kDa secreted 
glycoprotein that is expressed in yivo by the giant trophoblast cells of murine placentae 
during days 9-13 of gestation (Linzer et al., 1985, Lee et al., 1988 and Nilsen-Hamilton 
et al., 1991). Based on amino acid sequence homology MRP/PLF is a member of the 
prolactin-growth hormone gene family (Linzer and Nathans, 1984; Connor et al., 1989). 
Receptors for this protein occur in the uterus and their appearance in these organs 
correlates to the expression pattern of mrp/plf observed in murine placentae and in 
maternal blood (Nelson et al., 1994). MRP/PLF stimulates proliferation of mouse 
uterine cells in primary cultures (Nelson et al., 1994; Rosenzwieg and Nilsen-Hamilton, 
manuscript in preparation). Many mouse cell lines express this protein in response to 
various mitogens (Nilsen-Hamilton et al., 1980; Linzer and Nathans, 1983, 1984; 
Chiang and Nilsen-Hamilton, 1986; Fienup et al., 1988; Linzer and Wilder, 1987; 
Wilder and Linzer, 1989; Nilsen-Hamilton et al., 1988, 1991). The mitogens tested 
include serum, phorbol myristate acetate (PMA; also known as TPA) and growth 
factors such as epidemial growth factor (EGF), platelet derived growth factor (PDGF), 
transforming growth factor-a (TGF-a) and basic fibroblast growth factor (bFGF). While 
these growth factors are known to stimulate expression of MRP/PLF, transforming 
growth factor-p (TGF-P) inhibits its expression (Chiang and Nilsen-Hamilton, 1986). 
Basic FGF is a ubiquitous growth factor found in all tissues, tumors and cultured 
cells that have been examined (Rifkin and Moscatelli, 1989). Its wide distribution is 
paralleled by its many proposed biological functions which include: induction of ventral 
mesoderm, participant in neovascularization and wound healing, stimulator of cell 
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proliferation and increased cell migration. Basic FGF is expressed in vivo in the 
placenta (Sommer et al., 1987), bFGF receptors occur in murine placenta 
(Hondermarck et al., 1990) and the giant trophoblast cells of this organ is the only 
organ known to express mrp/pif (Lee et al., 1988). Moreover, bFGF and FGF 
receptors have been detected in mouse trophoblast outgrowths in culture (Haimovici 
and Anderson, 1993). Exogenous addition of bFGF enhances trophoblast outgrowths 
ijbkS). Mitogen regulated protein mRNA has been detected in the polyploid giant cells 
that are part of these differentiated outgrowths. These giant trophoblast cells that form 
part of the placenta are the only cells that are known to express mrp/plf /n vivo. 
Considering the observations that bFGF is a potent stimulator of mrp/plf expression 
in 3T3 cells and that this growth factor is expressed in the cells that make this protein 
in vivo lead us to the hypothesis that bFGF may be among the regulators of mrp/plf 
expression in vivo. 
Because of its wide distribution and a broad spectrum of biological functions it 
is reasonable to expect that bFGF may have a role in regulating the expression of 
several genes. Basic FGF stimulates the expression of plasminogen activator (Mignatti 
et al., 1989), interstitial and type I collagenase (Moscatelli et al., 1986), skeletal and 
smooth muscle a-actin, P-myosin heavy chain and atrial natriuretic factor in cardiac 
myocytes (Parker et al., 1992), decorin and type I collagen in normal and keloid 
fibroblasts (Tan et al., 1993) and Xbra, MyoD and muscle actin in Xenopus animal-cap 
(MacNicol et al., 1993), pj-Tiicroglobulin and mrp/plf genes in 3T3 and TNR-9 cells 
(Nilsen-Hamilton et al., 1980,1987 and 1988; Fienup et al., 1986). Cytoplasmic forms 
of bFGF increases expression of integrins pi, ocS and a6 (reviewed in Mason, 1994). 
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It is not dear how bFGF acts to regulate the expression of these genes. Basic FGF 
increases mrp/plf mRWK in 3T3 cells (Nilsen-Hamilton et a!., 1987) and we show here 
that one of the mrp/plf genes (the different foims are described below), mrp/plf3 is 
transcriptionally activated by this growh factor. One way to approach this question is 
to investigate beginning from the downstream end of the signal transduction cascade 
initiated by bFGF. Such an approach has been taken by Parker et al. (1992) in 
examining how bFGF activates the expression of the SkA gene in cardiac myocytes. 
They identified a bFGF response element that comprises three serum response 
element (SRE) motifs which resemble the canonical cfos SRE that enabled the 
promoter to be transcriptionally activated by bFGF. We have observed that mrp/plf is 
transcriptionally activated in stable reporter gene transfection assays (this report). 
However, the mr/yp/f promoter does not have any of the SRE motifs identified in the 
SkA promoter. This finding suggested that mrp/plf might be regulated by bFGF 
through an entirely different sequence. Because identification of this sequence would 
provide valuable insights into how this ubiquitous growth factor acts to influence the 
expression of specific genes in a tissue-specific manner we examined the mechanism 
by which bFGF acts to enhance transcription of mrp/plf. It has been estimated that 
there are between four and six (Wilder and Linzer, 1986; Linzer and Mordacq, 1987; 
Connor et al., 1989) mrp/plf genes in the mouse genome. The promoters for three of 
these have been cloned (Linzer and Mordacq, 1987; and Connor et al., 1989). Our 
investigation has revealed that these promoter sequences between -576 to +65 are 
over 97% identical. However, we show that only one of these promoters is activated 
by bFGF. Therefore, as well as identifying a new bFGF regulatory element that directs 
expression of a gene that is also expressed in a tissue-specific manner, this 
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investigation also sheds light on subtle differences in promoter sequence that enable 
only one copy among several copies of a specific gene to be activated by a growth 
factor. 
Results 
A bFGF Response Element is located In the mrp/ptf3 gene promoter 
During our investigation of the regulation of mip/plf gene expression by bFGF 
we observed that a 2000 bp promoter sequence of the mrp/plf3 gene fused to the CAT 
reporter gene was inducible by this growth factor upon stable transfection of the 
reporter plasmids in 3T3 cells (Figure 1a). So we hypothesized that a bFGF response 
element (FRE) was located in the mrp/plf3 promoter. Next we analyzed bFGF-
responsiveness of the longest available sequence (1100 bp) for the other two mrp/plf 
gene promoters, plf42 and plf149. These promoter sequences were not inducible by 
bFGF (Figure 1b,c). To determine whether sequence upstream of -1100 bp was 
required for bFGF activation chimeric promoters were constructed by fusing the -2000 
to -1100 bp sequence of mrp/plf3 to the 1100 bp sequences of plf42 and plf149. The 
presence of the additional 900 bp sequence did not activate the plf42 and plf49 
promoters. This indicated that the sequence upstream of -1100 bp may not be 
essential for bFGF-responsiveness. To test the hypothesis that a c/s-acting FRE is 
located downstream of -1100 bp of the mrp/plf3 promoter we constructed several 
reporter plasmids containing sequential deletions of the mrp/plfS promoter (Figure 
la). Our results suggested that the FRE is located between -353 and -81 bases. 
Similar analyses of deletion constructs up to -427 bp were performed on the plf42 and 
Figure 1. The Effect of bFGF in Stimulating CAT Activity From mrp/plf3, plf42 and 
p/f^ 49 Promoter Sequences 
3T3 ceils were co-transfected with 15 |ig of the indicated promoter sequences adjacent 
to a CAT reporter plasmid and a pRSVneo plasmid coding for neomycin resistance. 
Stable transfected cells were pooled (see Materials and Methods for details) and 
grown in DMEM containing 10% bovine calf serum. Two to three days later they were 
treated with bFGF (5 ng/ml) for 24 to 30 h. Control cells received no growth factor. 
CAT activity was measured in the cell lysates and normalized to protein concentration 
in the cell extracts. Results are indicated as the ratio of the specific CAT activity in 
lysates of FGF-treated cells over the values from lysates of control cells. The values 
are the mean of 2 to 6 experiments ± SO. 
(a) deletion analyses of mrp/p/f3 promoter sequence. 
(b) analyses oi mrp/plf3'plf42 chimeric promoter and plf42 deletion mutants. 
(c) mrp/plf3-plf149 chimeric promoter and plf149 deletion mutants. 
The range of background CAT activity (no CAT gene) was 108 to 165 cpm; the range 
of uninduced and induced CAT activities over background of the promoter-less pCAT 
Basic vector were 4 to 442 cpm/mg protein and 5 to 501 cpm/mg protein respectively; 
of mrp/plfS sequences were 431 to 21514 cpm/mg protein and 1013 to 55880 cpm/mg 
protein respectively: of plf42 sequences were 138 to 17152 and 5 to 7864 cpm/mg 
protein respiectively; and of plf149 sequences were 461 to 43726 cpm/mg protein and 
79 to 3372 cpm/mg protein respectively. 
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Length (bp) 
mrp/plfS _ 
2000 
1350 [M! 
1100 
[c^ 
[c^ 
I CAT 
799 
681 
609 
575 I cat 
427 —{^f 
353 &J 
81 -tM] 
46 tM] 
mrp/pl^  pif 42 
2000 I^T 
1100 [CAT 
799 fc^ 
681 
609 [cat 
575 [^Tl 
427 [M 
mrp/plf3 plf149 
2000 
1100 
799 
681 A^T 
609 
575 • 
427 jCAT 
CAT activity 
(fold/control) 
2.2 + 0.2 
2.3 + 0.3 
1.8 + 0.3 
1.9 t 0.2 
4.2 + 1.4 
2.1 + 0.4 
2.0 + 0.2 
3.2 + 1.1 
2.8 t 0.8 
0.4 + 0.2 
0.8 + 0.3 
0.6 + 0.1 
0.8 + 0.1 
0.4 + 0.2 
0.5 t 0.3 
0.7 + 0.1 
0.7 t 0.1 
0.6 t 0.2 
0.5 + 0.0 
0.7 + 0.3 
0.3 + 0.1 
0.3 + 0.1 
0.6 + 0.2 
0.7 t 0.2 
0.5 t 0.2 
61 
plf149 sequences. None of these sequences were inducible by bFGF (Figure 1 b,c). 
The bFGF Response Element (FRE) 
We compared the sequences between -353 and -81 of the mrp/plf3, plf42 and 
plf149 promoters (Figure 2) (for more details see Connor et al., 1989). Within this 272 
base sequence there are only 12 positions where variations occur between the 
mrp/plf3, plf42 and plf149 promoters (underlined in Figure 2a). At eight of these 
positions, mrp/plf3 and p//'42 have identical bases and variations occur only in four 
positions. Thus mrp/plf3 and plf42 are 98.5 % identical in this 272 bp region. Also, 
mrp/plf3 and plf149 are identical in only three of the positions of variation and differ at 
nine positions giving rise to an overall sequence identity of 96.5 %. plf42 and plf149 
differ from one another at all 12 positions and are 95.5 % identical. Since only the 
mrp/plf3 promoter is activated by bFGF, we looked for a region where the variation 
was specific for mrp/plf3. We found a unique base at position -173, where mrp/plf3 
has a T while both plf42 and plf149 have a C. Within the 8 bases upstream of -173, 
there are 3 positions where variations occur between mrp/plfS, plf42 and plf149. Thus 
within a stretch of 10 bases (-181 to -172), there are 4 points of variation which is the 
largest cluster of variation among the three promoter sequences. Within this cluster 
is also a base specific for mrp/plfS which is the only promoter that is bFGF-inducible. 
Therefore, we hypothesized that the FRE will encompass this region. To test this 
hypothesis synthetic oligonucleotides (FRE oligonucleotides) were synthesized which 
were identical in sequence to the mrp/plfS sequence -186 to -167 and which included 
these 10 bases (-181 to -171) with 5 flanking bases on either side (Figure 2b). 
Figure 2. The bFGF Response Element (FRE) 
(A) Comparison of the sequence -353 to -81 between the mrp/plf3, plf42 and plf149 
promoters. The sequence for and is shown in full. Wherever variations occur 
between mrp/plf3, plf42 and plf149 the bases in mrp/plf3 are indicated in bold, 
italicized and underlined letters and the bases of plf42 and plf149 are indicated 
respectively above and below the mrp/plf3 sequence. The FRE sequence is located 
between -186 and -167. The sequence information was obtained from Linzer and 
Mordacq (1987) and Connor et a|. (1989). 
(B) The sequence of the sense strand of the FRE, mutated FREs (ml FRE and 
m2FRE), plf42 and plf149 oligonucleotides. The mutated bases in the mFREs have 
been underlined. The bases in plf42 and plf149 that differ from the FRE (-186 to -167 
bases of the mrp/plf3 sequence) are indicated by bold italic letters. 
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(A) 
plf42 
mrp/plfS 
plf149 
-353 
TTAGAATATA TAAAATCCTG AAGGTAAAAA GGTCTATGGC 
plf42 -313 T 
mrp/plf3 ATAGCTATTT A7TTAAAGCA AGTAATTTCT ATCAGTCTTT 
plf149 C 
plf42 
mrp/plf3 
plf149 
plf42 
mrp/plfS 
plf149 
-273 
ATGAGGAAGA CATAGTTGTG GCTACTCACA GTATGATTTG 
-233 T 
TTTTAGTCAG AGCATGAACA TGAGATGAAJ. CiACATACATA 
C 
plf42 -193 -186 T CA C -167 
mrp/plfS GAACTGACTA TAICAGIGAA TCTAAAAAAT AAGATAAACC 
plf149 A TG C 
plf42 -153 G 
mtp/plf3 ATGAACTTAG AACTATATTA GTGTJCATGG TATCTAGGCT 
plf149 T 
plf42 -113 A T AT 
mrp/plfS ACTTAACCCT GAGGGAAAA4 TAATGGAAAT TA 
plf149 TA CA 
(B) 
FRE Oligonucleotide 
m1FRE Oligonucleotide 
m2FRE Oligonucleotide 
plf42 Oligonucleotide 
plf149 Oligonucleotide 
-186 -167 
5' CTATA TCAGTGAATC TAAAA 3' 
5' CTATA TCAGTGAACC TAAAA 3' 
5* CTATA ACAGTGAATC TAAAA 3' 
5' CTATA TCAGCAAACC TAAAA 3' 
5' CTATA ACAGTGAACC TAAAA 3' 
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Soluble Nuclear Factor(s) Bind the FRE 
To determine whetiier a soluble nuclear factor(s) induced by bFGF binds the 
FRE, electrophoretic gel mobility retardation assays were performed using nuclear 
extracts prepared from 3T3 cells after treatment with or without bFGF. The nuclear 
extracts were incubated with radiolabeled FRE oligonucleotide followed by 
polyacrylamide gel electrophoresis. One specific retarded band was observed when 
nuclear extracts from bFGF-treated cells were used (Figure 3). However, with nuclear 
extracts from control cells no band was observed (Figure 3). However, in some cases 
a weak band was observed with control extracts, which indicated marked reduction in 
the amount of soluble factors in untreated cells available for binding to the FRE. In 
certain other cases, the control nuclear extracts exhibited two bands, a major and 
minor band, the major band appeared to migrate slightly faster than the band observed 
with nuclear extracts from bFGF-treated cells (data not shown). Nuclear extracts from 
bFGF-induced cells prepared with varying concentration of KCI (0.8 to 1.6 M) appear 
to have a similar concentration of factors capable of binding to the FRE (Figure 3). In 
all other experiments nuclear extracts were prepared with 1.2 M KC!. Nuclear extracts 
were prepared from cells that were treated with human recombinant bFGF (USB Inc.,) 
also produced the same band shifts as were observed with bFGF-treated nuclear 
extracts. The shifted bands were specifically competed for by excess unlabeled FRE 
oligonucleotide (Figure 4). Next we tested plf42 and plf149 oligonucleotides that were 
identical to the sequence -166 to -167 of the respective promoters for their ability to 
compete with the FRE for nuclear factors. The plf42 oligonucleotide appeared to 
compete fairly well with the FRE (Figure 5). At 1x molar concentration the plf42 
oligonucleotide reduced the shifted band by 50% while at lOx concentration the shifted 
Figure 3. Nuclear Proteins form bFGF-treated Cells Specifically Bind to Radiolabeled 
FRE oligonucleotide 
Nuclear extracts from bFGF-treated 3T3 cells were prepared by the method of 
Chodosh (described in Ausubel et al.,1989) using the indicated concentrations of KCI. 
Extracts from control cells were prepared using 1.2 M KCI only. The nuclear extracts 
were mixed with ^P-labeled, double-stranded FRE oligonuleotide (0.5 ng) as 
described in Materials and Methods. Free DNA and protein-DNA complexes were 
separated by gel electrophoresis on a 4 % polyacrylamide gel (30:1 
acrylamide:bisacrylamide) and detected by autoradiography. -, probe only; C, control. 
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FRE Probe 
bFGF 
KCI (M) 0*8 1*0 1*2 1*4 1*6 1-2 
Figure 4. Competition for bFGF-treated 3T3 Cell Nuclear Protein Binding by 
Unlabeled FRE Oligonucleotide 
Nuclear extract firom bFGF-treated cells was incubated with 1x, 5x, 10x, 50x and 100x 
molar excess of double-stranded unlabeled FRE (over labeled FRE) for 10 min 
followed by incubation with ^P-labeled FRE double-stranded oligonucleotide as 
described in Experimental Procedures. Free DNA and protein-DNA complexes were 
separated by gel electrophoresis and detected by autoradiography. -, no competitor. 
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Competitor 
DNA 
FRE Probe 
FRE 
1x 5x lOx 50x lOOx 
Figure 5. Competition by plf42 and AP1 Double-stranded Oligonucleotides for Binding 
to Nuclear Factors from bFGF-treated cells 
Nuclear extracts from bFGF-treated 3T3 cells were incubated with 1x and 10x molar 
excess (relative to the ^ P-labeled FRE probe) of either plf42, AP1, or the non-specific 
AssTaa double-stranded oligonucleotides (for sequence see Experimental Procedures) 
and prior to the addition of labeled FRE oligonucleotide. As a control unlabeled FRE 
was used as a specific competitor at 1x and 10x molar excess of labeled probe. Free 
DNA and protein-DNA complexes were separated by electrophoresis and detected by 
autoradiography. Lane 1, probe only; -, no competitor; C, control cell nuclear extract. 
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NUCLEAR i T 
EXTRACT ^ 
Competitor - - fi^e Plf42 API AT -
DNA 
1x lOx 1x lOx 1x lOx 1x lOx 
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band was reduced by 75%. However, the FRE specific competitor reduced the shift 
by 70% and >98% at the respective concentrations. The plf149 oligonucleotide 
exhibited no competition with the FRE for nuclear factor interaction (data not shown). 
Since bFGF is reported to increase cfos and cjun expression (Buchou and 
Mester, 1990) we wanted to determine whether these transcription factors are part of 
the complex that binds the FRE. Therefore, an oligonucleotide that contains the API 
sequence was used as a competitor for the FRE in gel mobility shift assays. The API 
oligonucleotide did not compete for factors that bind the FRE (Figure 5) thereby 
suggesting that the API transcription factor may not be part of the nuclear factor 
complex that binds the FRE. 
We also tested the ability of radiolabeled plf42 and plf149 oligonucleotides to 
bind to nuclear proteins from bFGF-treated and -untreated cells. Both plf42 and plf149 
oligonucleotides did not exhibit a mobility shift, indicating that they do not bind nuclear 
factors from either control or bFGF-treated cells (Figures). 
To determine whether the unique base in the FRE was crucial for binding of 
nuclear factors, the T (position -173, Fig 2b) in the FRE was converted to a C (which 
is found in this position in both plf42 and plf149) and the mutant FRE (ml FRE) was 
used in mobility shift assays. The ml FRE reduced the band shift by >90 % (Figure 7). 
In the second mutant oligonucleotide, m2FRE, the base T (position -181) which is 
identical for both FRE and plf42 oligonucleotide was changed to A, the base that is 
found in plf149 oligonucleotide in this position. plf149 oligonucleotide, which is a 
"natural" double mutant in which both the bases are altered, was used as a negative 
control. Both m2FRE and plf149 oligonucleotide were capable of binding factors from 
control, but not bFGF-treated, cell nuclear extracts exhibiting a strong shift as a faster 
Figure 6. Gel Mobility Shift Assay Using Labeled plf42 and plf149 Oligonucleotides 
as Probes. 
Nuclear extracts from bFGF-treated and untreated 3T3 cells were incubated with 
labeled, double-stranded plf42 and plf149 oligonucleotide (0.5 ng). As a control these 
extracts were also incubated with labelled FRE. Free DNA and protein-DNA 
complexes were separated by gel electrophoresis and detected by autoradiography. 
probe only; C, probe + nuclear extract from untreated cells; F, probe + nuclear 
extract from bFGF-treated cells. 
73 
PROBE FRE Plf42 Plf149 
NUCLEAR 
_ C F _ C F . C F 
EXTRACT 
W 0 
Figure 7. Gel Mobility Shift Assay Comparing Binding of Radiolabeled FRE, m1 FRE, 
m2FRE and p/fy 49 Oligonucleotides. 
Nuclear extracts from control and bFGF-treated cells were incubated with labeled, 
double-stranded FRE and mutant FREs (m1FRE, m2FRE) and plf149 oligonucleotide 
("natural" double mutant)(0.5 ng probe). Free DNA and protein-DNA complexes were 
separated by acrylamide gel electrophoresis and detected by autoradiography. 
probe only; C, probe + control nuclear extract; F, Probe + nuclear extract from bFGF-
treated cells. 
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migrating band (Figure 7). A gel shifted band conresponding to that obtained with the 
FRE was not observed with either of the three mutant oligonucleotides. However, in 
experiments involving other batches of control extracts, plf149 oligonucleotide did not 
show any gel shifted bands (for example see lane 8, Figure 6). Therefore, the 
variation observed in this experiment may be attributed to the variation in the batch of 
control extract used. 
The FRE Competes for nuclear factors In vivo 
To detenmine whether the FRE can compete for specific nuclear factors in vivo, 
competition analyses were perfomned in 3T3 cells that were stably transfected with the 
CAT reporter plasmid that had -353/+65 bases of the mrp/plf3 promoter fused to the 
CAT gene. These stabiy transfected cells were transiently transfected with FRE, plf42 
and f^149 oligonucleotides followed by treatment with or without bFGF. Transfection 
with FRE significantly reduced bFGF activation of the promoter (Figure 8) thereby 
providing evidence that the FRE does bind transcription factors that are induced or 
activated by bFGF. 
Nuclear Factors from EGF, PDGF and PMA-induced Cells Also Bind the FRE 
To determine whether the FRE specifically bound nuclear factors from bFGF-
induced cells, nuclear extracts were prepared from EGF, PDGF and PMA-treated cells. 
The FRE was incubated with these extracts and mobility shifts were perfomned. 
Nuclear factors from these mitogen-treated cells produce two shifted bands as 
observed with bFGF-treated nuclear extracts (Figure 9). The pif42 and plf149 
oligonucleotides did not exhibit binding to nuclear factors from these mitogen 
stimulated cells (Figure 9). We tested if the AP1 factors, Fos and Jun were part of the 
Figure 8. In vivo Oligonucleotide Competition Analyzing the Effects of FRE, plf42, 
and plf149 Sequences upon the Activation of mrp/plfS-drwen CAT Activity by bFGF. 
Fibroblasts that were stably transfected with the CAT reporter plasmid carrying the 
-353/465 sequence of the mrp/plf3 promoter fused to the CAT gene were used in this 
experiment. These cells were transiently transfected with 20 |ig of the double-
stranded oligonucleotides - FRE, plf42, plf149, or poly(dl-dC). As a control for 
variation in transfection efficiencies from one dish to another, the cells were also co-
transfected with pSV40LacZ, a 3-galactosidase expressing plasmid. One day after 
transfection the cells were treated with 5ng/ml bFGF for 24 to 30 h following which cell 
lysates were prepared. The CAT activity in the cell lysates is shown as the ratio of the 
specific CAT activity in the lysates from bFGF-treated cells over the specific CAT 
activity in the control, untreated cells. Bars represent mean ± SD (n=2). 
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Figure 9. Nuclear Extracts From EGF, PDGF, and PMA -induced 3T3 Cells Also Bind 
the FRE but not the plf42 and plf149 oligonucleotides. 
Nuclear extracts from cells treated with EGF (E), PDGF (P) or PMA were incubated 
with labeled, double-stranded FRE, p/f42 and plf149 oligonucleotides. The free DNA 
and DNA-protein complexes were separated by gel electrophoresis and detected by 
autoradiography. As a control these probes were also incubated with nuclear extracts 
from bFGF-treated (F) and-untreated control (C) cells. 
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complex observed with these extracts by using the API oligonucleotide as a 
competitor. AP1 oligonucleotide did not compete for binding with nuclear factors from 
cells induced with PMA (Figure 10). API oligonucleotide did not compete with the 
FRE for nuclear factors from EGF and PDGF stimulated cells as well (data not shown). 
Discussion 
Previous studies have shown that bFGF stimulates an 8-fold increase in 
MRP/PLF mRNA in 3T3 cells (Nilsen-Hamilton et al., 1987). This study provides 
evidence that the promoter sequence of one of the MRP/PLF genes, mrp/plf3, is 
transcriptionally activated by this growth factor in spite of there being greater than 96% 
sequence identity among the promoters of the three mrp/p/f genes analyzed. 
Apparently mrp/plf3 promoter has undergone a mutation to enable it to be specifically 
activated at the transcriptional level by bFGF. Presently, it is unclear whether, this 
acquired transcriptional regulation is relevent in the physiological context. The 
proteins encoded by the three genes differ in only two amino acids out of 195 in the 
mature protein (Connor et al., 1989). But our finding that bFGF activates the 
transcription of one and not the other two, leads to the speculation that the small 
variability in the promoter and mature protein may be significant. This study provides 
a basis for further investigations on the mechanism(s) of regulation of expression of 
a specific protein encoded by multiple genes. 
The element through which bFGF mediates the transcriptional activation of 
mrp/plf3 is different from that reported in the skeletal muscle a-actin {Ska) gene 
(Figure 11). In the skeletal muscle background full promoter activity of the Ska 
promoter requires each of three CC[A/T]eGG motifs similar to the serum response 
Figure 10. The AP1 Oligonucleotide Does Not Compete With the FRE Oligonucleotide 
for Binding to Nuclear Extracts From Cells Treated With PMA 
Nuclear extracts from cells treated with PMA were incubated first with unlabelled AP1 
oligonucleotide followed by incubation with labeled, double-stranded FRE 
oligonucleotide. Competition with AP1 oligonucleotide was also performed with control 
nuclear extracts (C). As a control the probe was also incubated with nuclear extracts 
from bFGF-4reated cells (F) without any competition with AP1 oligonucleotide. The free 
DNA and DNA-protein complexes were separated by electrophoresis and detected by 
autoradiography as described before. Lane 1, probe only; no competitor. 
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FRE -186 CTATATCAGTGAATCTAAAA -167 
GATATAGTCACTTAGATTTT 
I J 
SRE3 -190 GCAGACGCTCCTTATACGGCCCGGCCTC -163 
CGTCTGCGAGGAATATGCCGGGCCGGAG 
SRE2 -145 CCAGGAGCGCCTTCTTTGGGCAGCGCCG -118 
GGTCCTCGCGGAAGAAACCCGTCGCGGC 
SRE1 -100 GCCCGACACCCAAATATGGCGACGGCCG -73 
CGGGCTGTGGGTTTATAGCGCTGCCGGC 
cfos -318 ACAGGATGTCCATATTAGGACATCTGCG -291 
SRE TGTCCTACAGGTATAATCCTGTAGACGC 
Figure 11. Comparison of the FRE sequence to the distal, central and proximal serum 
response elements (SRE3, SRE2 and SRE1 respectively) within the chicken Ska 
promoter that is required for bFGF activation of the promoter. The cfos SRE sequence 
is also shown. The CC(A/T)eGG motifs in the SREs have been underlined. The FRE 
sequence is boxed and is shown with its 6 bp flanking sequences. The SRE 
sequences were obtained from Parker et al., 1992. 
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element (SRE) found in cfos promoter (Parker et al., 1990; 1992). In cardiac 
myoblasts bFGF can stimulate the Ska promoter with the proximal SRE, SRE1 and 
does not require the central and distal SREs. Our study has uncovered a second 
bFGF response element, the FRE. It is intriguing, though not surprising, that this 
growth factor acts at least through two DNA promoter elements. Firstly, bFGF is an 
enigmatic growth factor appearing to act through more than one signal transduction 
pathway; it can signal through the Ras/Raf/Map kinase pathway (MacNicol et al., 
1993); by association with phospholipase c^* (reviewed in Mason, 1994); it is 
translocated to the cytosol, nucleus (Baldin et al., 1990; Dono and Zeller, 1994) and 
nucleolus (Bouche et al., 1987); it activates transcription of genes in a cell-free in vitro 
ti'anscription system. Secondly, both mrp/p/f and S^a genes are expressed in vivo in 
a tissue specific manner and therefore the different elements that mediate regulation 
by bFGF of these two genes may ensure specificity of gene expression. Recently, Liu 
and Green (1994) have shown that the adenovirus El a protein, a transcription factor, 
can interact with several classes of DNA-binding domains as a result of which it is 
recruited to diverse promoter sequences. Such a situation can be visualized for 
transaiptional activation by bFGF through diverse promoter elements. bFGF may 
activate specific transcription factor(s) which interact(s) with other factor(s) expressed 
in cells in a tissue specific manner which will allow recognition of response elements 
for a specific gene in a particular cell type. 
Growth factor signalling through the Ras/Raf/Map Kinase pathway is known to 
activate transcription factors that include FOS and JUN (reviewed in Blenis, 1993). 
However, the protein(s) that bind the FRE do(es) not include the API complex, FOS 
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and JUN, as indicated by the AP1 oligonucleotide competition experiments. This 
finding does not, however, exclude the possibility that the FOS and/or JUN may be 
part of the FRE binding complex in association with other transcription factors or FOS 
and JUN may bind outside of the FRE oligonucleotide sequence. Furthermore, it is 
most likely that the FRE binding complex may not include SRF and F-Act1 (also known 
as YY1), the transcription factors known to interact with the SRE, the element that 
mediates bFGF activation of the Ska promoter (Parker et al., 1992) because the FRE 
sequence does not resemble that of the SRE. 
A key finding of this study is that the FRE is functional in intact cells. This is 
supported by in vivo competition studies that showed wild type FRE inhibited bFGF 
stimulation of the -353/465 sequence of the mrp/plf3 promoter while mutant FRE, plf42 
and f^ 149 oligonucleotides did not. It will be of interest to determine whether the FRE 
can confer bFGF-inducibility to heterologous promoters. 
FRE may not be specific for bFGF. It is recognized by nuclear proteins from 
EGF, PDGF and PMA stimulated cells. It may therefore, be a general mitogen 
response element. This observation is not surprising. Both EGF and PDGF, like 
bFGF transduce intracellular signals upon activation of its receptor through the 
Ras/Raf/Map Kinase pathway (reviewed in Blenis, 1993) and therefore, may be 
activating similar or identical transcription factors that will go on to activate late 
responsive genes like mrp/plf. Like PMA, bFGF can also activate protein kinase C 
(Presta et al., 1989, Buchou and Mester, 1990) which might explain the FRE binding 
activity identified in nuclear extracts from cells treated with PMA. However, this 
complex does not include the API complex as evidenced by the API oligonucleotide 
competition experiments. 
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The FRE sequence has been identified in the sequence of several genes (Table 
1) either in the promoter, exon, intron or 3' sequence. It remains to be determined 
whether this sequence has any role in regulating the expression of these genes. 
In conclusion, we have identified a promoter sequence, the FRE, through which 
bFGF acts to stimulate transcription of the mr/i/plfS gene. This sequence not only 
binds nuclear factors from bFGF stimulated cells but also from those stimulated with 
other mitogens such as EGF, PDGF and PMA, leading to the speculation that it may 
be general mitogen response element. 
Experimental Procedures 
Cell Culture and Materials 
Swiss 3T3 and cos cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% bovine calf serum and 10 lo/ml each of penicillin and 
streptomycin (GIBCO/BRL) The cells were maintained in a humidified atmosphere 
containing 10% COjand 90% air at 37°C. 3T3 cells that were stable transfected were 
maintained in medium that also contained 350 |ig/ml G418 (GIBCO/BRL). They were 
free of mycoplasma contamination as determined by ^H-thymidine or the Hoechst 
33258 fluorescent dye assay. Bovine basic FGF (bFGF) was a generous gift from 
0. Gospadorowicz, University of California, San Diego. 
Plasmld Construction 
The sequence -2000 to +65 bp of mrp3/plf3 was removed from pCKT-17-2/p2p 
by Cla I and Pst I double digest and ligated to pCAT Basic vector (Promega, Inc). 
Prior to ligation pCAT Basic plasmid was first cut with Hind III, blunt-ended with Klenow 
fragment, ligated to Cla I linkers and then cut with Cla I and Pst I. The pCKT-17-2/p2p 
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Table 1. Genes having sequence identity to the FRE either in promoters, exons, 
introns or their 3' ends. Genes were identified using the BLAST search 
(Altschul et al., 1990). 
Gene Promoter/Exon/ 
lntron/3* end 
Soecies Position Seauence 
mrp/plf3 promoter mouse -181 ATCAGTGAATCT 
arylsulphatase exon 1 sea urchin 184 ATCAGTGAATCT 
c-myc 3' region . human 472 AGATTCACTGAT 
(minus strand) 
abl exon 1b human 5525 ATCAGTGAATCT 
mhc exon carp 277 ATCAGTGAATCT 
transin-2 promoter rat -585 AGATTCACTGAT 
(minus strand) 
mp6d9 human 83 ATCAGTGAATCT 
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construct was generated in the laboratory from the plasmid p2pCAT (gift from D.T. 
Denhardt) that carried -2000 to +65 bp mrp/plf3 sequence. -1350, -1100, -799, -681, 
-609, -576, -427, -353, -81 and -46 deletion mutants were generated from 
mrp3(2kb)/CAT Basic by digesting with EcoRI (-1350 and -1100), Avail (-799), Hindlll 
(-681 and -609), EcoRV (-575), BsmFI (-427), Apol (-353), Afllll (-81) and Bsu36l (-46) 
restriction enzymes. -1100 to +65 bp fragments of plf42 and plf149 were obtained by 
digesting plf42CAT and plf149CAT plasmids (gift from D.L.H. Linzer) with Hindlll and 
Pst I. These fragments were ligated to Hindlll/PstI cut pCAT Basic vector to generate 
plf42CAT Basic and plf149CAT Basic plasmids. -799, -681, -609, -575 and -427 
deletion mutants of both plf42 and plf149 promoters were obtained by digesting 
plf42CAT Basic and plf149CAT Basic with Avail (-799), Hindlll (-681 and -609), EcoRV 
(-575), BsmFI (-427) restriction enzymes. The mrp/plf3-plf42 and mrp/plf3-plf149 CAT 
Basic chimeric promoter constructs were generated as follows: 1165 bp EcoRt-Pst I 
fragment from plf42CAT Basic and pif149CAT Basic were separately ligated to a 900 
bp Cla I- EcoRI fragment from mrp3(-2000/-1100)/pBKSII and to a Cla l-Pst l-cut pCAT 
Basic vector in a three-piece ligation reaction. Heterologous promoters were 
constructed by cloning the appropriate sequences into the plasmid pt18TKCAT (gift 
from S. Tapscott) which has -109 to +51 sequence of the herpes thymidine kinase 
promoter upstream of the CAT gene. Site-directed mutations wherever indicated were 
perfonned by PCR using the method described by Heriitz and Koenen (1990) and a 
Hybaid Thennal Cycler. 
Stable and Transient Transfections 
3T3 cells were plated at a density of 2.5 x 10  ^cells per 100 mm dish. Cells 
were cotransfected with the reporter plasmid in combination with pRSVneo at a 5:1 
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molar ratio (reporter plasmidipRSVneo) with the total DNA per dish being 20 ^g. 
Transfections were performed using the calcium phosphate procedure as described 
by Kingston (1987). Stable transfected cells were selected by adding 350 ^ g/ml G418 
in the medium. After 4 to 6 weeks of selection the stably transfected cells were pooled 
and frozen in liquid nitrogen. To assay the transfected cells for bFGF induction, the 
cells were plated at 2500 cells per cm  ^in 60 mm dishes in DMEM containing 10% 
bovine calf serum. Three to 4 days later, bFGF was added at 5 ng/ml. Twenty four to 
30 h later the cells were harvested and lysates were prepared. COS cells were plated 
at 1.5 X 10° cells per 60 mm dish and transiently transfected with heterologous 
promoter plasmids using the DEAE-Dextran procedure. Fresh DMEM containing 10% 
bovine calf serum was added to the cells post-transfection. Two days later they were 
treated with bFGF at 5 ng/ml for 24 h following which the cells were harvested and 
lysates prepared for the CAT assay. 
CAT Assay 
Cells were lysed in 0.25M Tris.CI, pH 8.0 by three freeze-thaw cycles. Lysates 
were heated to 68  ^and the CAT assay was peformed by the method of Seed and 
Sheen (1989) using ^ ^C- chloramphenicol and butyryl CoA. 
Oligonucleotides and Probes 
Oligonucleotides were custom synthesized by Midland Certified Reagent 
Company. The double-stranded oligomer corresponding to the bFGF response 
element (FRE) was constructed by annealing the following two oligonucleotides: 5'-CT 
ATATCAGTGAATCTAAAA-3' and S'-TTTTAGATTCACTGATATAG-S'. This sequence 
corresponds to -167 to -186 of the mrp/plf3 promoter sequence. Double-stranded 
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oligomers corresponding to the identical regions of the plf42 and plf149 promoter 
sequences were constructed by annealing the following pairs of oligonucleotides: 5'-
CTATATCAGCAAACCTAAAA-3' and 5'-TTTTAGGTTTGCTGATATAG-3': 5'-CTAT 
AACAGTGAACCTAAAA-3' and S'-TTTTAGGTTCACTGTTATAG-S'. Annealing to fomi 
double stranded oligomers were performed in STE (lOOmM NaCI and 1 mM EDTA, 10 
mM Tris.CI. pH 8.0). Mutant FREs, mIFRE (5'-CTATATCAGTGAACCTAAAA-3'), and 
m2FRE (5'-CTATAACAGTGAATCTAAAA-3') were annealed to their respective 
complimentary strands. The non-specific competitor, AsjTsg oligonucleotide (5-
I I I I 111GGCAAAAAAAAAAACAA AAATAGTAA-3') along with its complementary 
strand was a gift from Shawn Ahmed. Purified double stranded API consensus 
oligonucleotide (5'-CGCTTGATGAGTCAGCCGGAA-3') was obtained from Promega 
Corp. All oligonucleotides used for gel mobility shift assays were purified by resolving 
them through urea-polyacrylamide gel electrophoresis. Following extraction from the 
gel, the urea and salts were removed using the Sep-Pak C^s^hromatography column 
(Waters Chromatography Division) prior to annealing or labelling. For gel mobility 
assays single-stranded purified oligomers were phosphorylated using T4 
polunucleotide kinase (Pharmacia) in the presence of [Y-^ P]ATP (3000 Ci/mmol; NEN 
Dupont), 70 mM Tris.CI, 7.6,10 mM MgCI2 and 5 mM DTT. Oligomers were annealed 
in STE buffer. Unincorporated label and single-stranded probes were removed by gel 
electrophoresis. The probes were precipitated by ethanol and stored in STE at 4''C. 
Preparation of Nuclear Extracts 
Nuclear extracts were prepared from growing 3T3 cells stimulated or 
unstimulated with bFGF (5 ng/ml) for 6 h as described by Abmayr and Workman 
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(1987). Nuclear proteins were extracted with increasing salt concentrations (0.8,1.0, 
1.2,1.4, and 1.6 M KCI). The extract that contained proteins capable of binding the 
bFGF response element was identified using the filter-binding assay as described by 
Papoulas (1987). This extract was then used for the mobility shift and DNAse footprint 
assays. 
DNA-binding Gel Mobility Shift Assay 
Binding reactions (20 |il) contained 300 iig/ml BSA, 25 mg protein (nuclear 
extract), 60 mM KCI, 1 mM EDTA, 4 mM MgClj., 0.4 mM PMSF, 0.1 mM DTT, 2 |ig 
poly(dl-dC),poly(dl-dC), 20% glycerol, 4mM Tris.CI, 12 mM HEPES-NaOH, pH 7.9 and 
0.5 ng probe. Wherever indicated the reaction mixes also included specific and non­
specific competitiors as controls for specificity of the binding reaction. The reaction 
mixes were incubated at SO^C for 20 min. DNA-protein complexes were separated 
from free probe by electrophoresis on 4% polyacryalmide gel (80:1 acrylamide : 
bisacrylamide) in 1.0X Tris-glycine buffer (2.68mM EDTA, 380mM glycine, 2.5% 
glycerol, 50mM Tris base, ph 8.5). Gels were run at 10 V/cm, dried under vacuum and 
either exposed to a PhosphorScreen (Molecular Dynamics) and analyzed on a 
Phosphorlmager or exposed to Kodak X-Omat AR film with intensifying screen at room 
temperature. 
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GENERAL CONCLUSIONS 
The focus of this research was to elucidate the mechanism(s) by which 
MRP/PLF is regulated by bFGF. MRP/PLF itself is a growth factor that stimulates 
proliferation of murine uterine cells. It is expressed in vivo in a tissue specific 
manner only in the giant trophoblast cells of murine placentae. It has been implicated 
to have a role in murine development. On the other hand, bFGF which is expressed 
in a wide range of tissues and organs (Rifkin and Moscatelli, 1989) is found in all 
vertebrates examined. There are several variants of this growth factor. Upon binding 
to its receptor its signal transduction appears to occur through more than one pathway 
(Moses, 1994). However, the pathways are not fully understood. By studying the 
mechanisms of regulation of mrp/plf genes by bFGF we can not only derive gainful 
insights into the regulation of this gene in vivo but also learn more about the 
mechanism of action of this ubiquitous growth factor. 
My research has demonstrated the following: first, only one form (PLF1) of 
MRP/PLF protein is expressed in 3T3 cells in response to bFGF; the genes that 
encode this form, plf42 and/or plf149 is/are not transcriptionally activated by this 
growth factor; however, bFGF-stimulated cells exhibit a gradual increase in PLF1 
mRNA with maximum levels occuring at 16 h of incubation; the increase in PLF1 
mRNA is not attributable to bFGF-induced stabilization; bFGF increases the rate at 
which PLF1 heterogenous nuclear RNA (hnRNA) is processed which probably results 
in translocation of mature RNA into the cytoplasm; a kinetic argument together with 
previous reports that suggest only translatable RNA is translocated to the nucleus 
(Miller and Hanover, 1992) can be applied to explain the increase in PLF1 mRNA 
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observed upon bFGF administration. My studies therefore demonstrate that bFGF 
regulates the m^plf gene that encodes PLF1 form of the protein (i.e, plf42 or plf149) 
at the posttranscriptional level; and that bFGF increases the rate at which the PLF1 
hnRNA is processed in the nucleus. In control cells PLF1 hnRNA is conceivably not 
processed to completion and therefore is not translocated and may eventually be 
targeted for degradation. This is the first report of a growth factor induced regulation 
of gene expression by mechanism that involves processing of hnRNA within the 
nucleus. 
Upon analyses of the promoter sequences from the three mrp/plf genes in 
stable transfection assays utilizing CAT as reporter I observed that one of them, 
mrp/plf3 ^ as transcriptionally activated by bFGF. The mRNA that corresponds to the 
protein encoded by this gene, however, is not expressed in these cells. This 
observation suggested that the endogenous mqj/plf3 gene may have undergone some 
modifications effecting its expression in these cells and that in certain situations the 
promoter is capable of being activated. This hypothesis was supported by my 
observation that all three forms of the gene are expressed in mouse placentae. By 
performing systematic deletion analyses of the three promoters I was able to identify 
a bFGF response element (FRE) in the mrp/plf3 promoter (-181 to -172). This element 
is a 10 bp long sequence (TCAGTGAATC) and does not resemble the sequence 
reported to mediate bFGF activation of the skeletal muscle a-actin gene promoter 
{Parl<er et al,, 1992). Across the corresponding sequence the plf42 and plf149 
promoter sequences are different from the FRE in 3 and 2 bases respectively. FRE 
specifically recognizes nuclear factors extracted from the nucleus of bFGF-stimulated 
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cells. The complex that binds the FRE does not include the AP1 transcription factor 
complex. This observation is interesting because previous reports indicate that bFGF 
increases the expression of c-FOS and c-JUN (Buchou et al., 1990). The FRE is an 
active element because it can compete with factors /n vivo. Cells that are stimulated 
by other growth factors such as epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) and by the tumor promoter, phorbol myristyl acetate (PMA), also 
induce the transcription factors that recognizes the FRE. Therefore, the FRE may be 
a general mitogen response element. This observation is not surprising because 
these mitogens have some common signal transduction pathways (Buchou et al., 
1990; MacNicol et al., 1993; Mason, 1994) with bFGF. The promoter analyses of the 
/n/p/)D/f genes demonstrated that bFGF transcriptionally activated one of them thereby 
indicating that this growth factor can specifically regulate one or more forms of mrp/plf 
genes either transcriptionally or posttranscriptionally. 
Understanding regulation of gene expression is fundamental to our 
understanding of cellular functions during healthy and diseased states. Gene 
expression is modulated by numerous factors, growth factors being a class among 
them. These modulators can regulate the expression of specific genes by regulating 
transcriptional or posttranscriptional events. Transcriptional control can be enforced 
at initiation, elongation or tennination. Posttranscriptional control can occur at 
processing of hnRNA, polyadenylation, transport of mRNA to the cytoplasm, turnover, 
translation and posttranslational events. My observation that bFGF regulates mrp/plf 
expression at the level of processing of the PLF1 hnRNA lays the foundation for future 
research aimed at elucidating the mechanisms utilized by this growth factor to 
stimulate processing. Nuclear RNA processing consists of pre-mRNA (hnRNA) 
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synthesis, splicing and co or posttranscriptional modifications of the pre-mRNA 
involving the following: capping at the 5' end; methylation at the N° position of certain 
residues; cleavage and polyadenylation and eventually degradation (Maquat, 1991). 
It would be interesting to determine which of these of these events are regulated by 
bFGF. Previous studies have demonstrated that pre-mRNA splicing factors and 
hetergenous nuclear ribonucleoproteins are recruited from sites of nuclear storage 
and/or assembly to sites of active transcription or to locations of pre-mRNA (Jimenez-
Garcia and Spector, 1993). It is tempting to postulate a testable hypothesis that bFGF 
may act to stimulate this recruitment to mrp/plf hnRNA thereby promoting its 
processing. It has been suggested that the nucleus may be able to assess the 
translatability of an mRNA and modulate its export accordingly (see Miller and 
Hanover, 1992 for references). It is possible that in the absence of bFGF, the mrp/plf 
hnRNA is rendered untranslatable and therefore is not translocated to the cytoplasm. 
It will of interest to determine if this is true and if it is to determine how it is rendered 
untranslatable. 
Identification of the FRE will allow future research aimed at delineating the 
nature of the transcription factors that mediates the bFGF response. The molecular 
weight of the complex can first be determined followed by identification of individual 
protein(s) using existing antibodies to known transcription factors, purify new factor(s) 
and clone the gene(s) that encodes them. These would provide valuable insights into 
transcriptional mechanisms. During the course of my investigation, I have generated 
several stably transfected cell lines having different lengths of the mrp/plf3 (-2000 to 
-46/+65 bp), plf42 and plf149 (-1100 to -427/+65 bp) promoter sequences along with 
CAT gene integrated in the genome. Using these cell lines efforts can be undertaken 
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to investigate the regulation of these promoters by various agents. For instance, 
mrp/plf expression is stimulated by EGF, PDGF, transforming growth factor-a and 
inhibited by transforming growth factor- .^ Transcriptional activation of the promoters 
by these factors can be evaluated and relevent elements characterized. 
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